Vascular Specialist—February 2022

21 CORNER STITCH Trainee competency Diversity while in training: Is it just yet another box to check?

Vol.18 No.02 February 2022 Official Publication

www.vascularspecialistonline.com

6

Featured in this issue:

$

NURSING COST INCREASE (PER MONTH):

VITAL SIGNS

Endovation

COMMENTARY Sex discordance and postoperative outcomes

COVID-19 IMPACTS

SPECIAL ISSUE

1

12

RADIATION PROTECTION Mask aimed at reducing exposure gains traction

$4.9 $13.6 million in 2020

million in 2021

2

JVS Special Session

SVS Postgraduate Education Committee

17 VAM Two innovative new session offerings

178%

a

jump

Skyrocketing vascular nursing costs hammer vascular division's financial bottom line

BY BRYAN KAY

BY BRYAN KAY

THE PROFIT MARGIN OF A VASCULAR SURGERY DIVISION at a prominent health system in New Orleans was severely eroded during the COVID-19 pandemic period—despite consistent revenue generation throughout—as nursing labor costs dramatically escalated, according to a deep financial analysis carried out by a local research team.

The investigators, led by members of the academic vascular surgery practice at Ochsner Health, looked at the division’s total profit margin across both hospital and outpatient clinics, as well as totals for vascular surgery nursing unit expenses, nursing unit See page 10

COMPLEX TAAA

US ARC IDE registry reports better survival vs. real-world data after endovascular repair

Patients treated in Food and Drug Administration (FDA)approved investigational device exemption (IDE) trials for complex thoracoabdominal aortic aneurysms (TAAAs) in the U.S. Aortic Research Consortium (ARC) had better 30day and one-year survival compared with those recorded in the real-world Vascular Quality Initiative (VQI) registry, new data presented at the 2022 Southern Association for Vascular Surgery (SAVS) annual meeting revealed.

Seepage page 0–0 8–9 See

Vascular Specialist 9400 W. Higgins Road, Suite 315 Rosemont, IL 60018

CHANGE SERVICE REQUESTED

Presorted Standard U.S. Postage PAID Permit No. 384 Lebanon Jct. KY

GUEST EDITORIAL

Silence is golden—but does self-imposed silence lead to burnout?

BY BHAGWAN SATIANI, MD

Burnout is associated with silence in various contexts. It is called the silent crisis, the silent epidemic, or the silent killer. What is not talked about is the pressure or fear at work, whether professional or personal, that can lead to avoidance behavior and self-imposed silence. Surgical residents have been reported to have burnout rates >60%, and it is likely that causative factors include the pressure or fear at work. My concern has to do with silence associated with physician employees in non-clinical roles at the individual level.

TO THIS END, THE EFFECTS OF SILENCE ON burnout were studied in 600 adults.1 Four differentially motivated types of silence (acquiescent, quiescent, prosocial, and opportunistic) were studied with three components of burnout (depersonalization, emotional exhaustion, and perceptions of reduced personal accomplishment). Pro-social and opportunistic types of silence were self-imposed, whereas acquiescent and quiescent silence were forced. The authors concluded that silence likely leads to burnout, not the other way around.

It is also likely that one of the critical factors leading to burnout in employed physicians is self-imposed silence. As an employee, their ability to speak out or “voice” is defined as the “discretionary communication of ideas, suggestions, concerns, or opinions about work-related issues with the intent to improve organizational or unit functioning.”2 In contrast, employee “silence” is the “conscious withholding of information, suggestions, ideas, questions, or concerns

VASCULAR SPECIALIST Medical Editor Malachi Sheahan III, MD Associate Medical Editors Bernadette Aulivola, MD, O. William Brown, MD, Elliot L. Chaikof, MD, PhD, Carlo Dall’Olmo, MD, Alan M. Dietzek, MD, RPVI, FACS, Professor Hans-Henning Eckstein, MD, John F. Eidt, MD, Robert Fitridge, MD, Dennis R. Gable, MD, Linda Harris, MD, Krishna Jain, MD, Larry Kraiss, MD, Joann Lohr, MD, James McKinsey, MD, Joseph Mills, MD, Erica L. Mitchell, MD, MEd, FACS, Leila Mureebe, MD, Frank Pomposelli, MD, David Rigberg, MD, Clifford Sales, MD, Bhagwan Satiani, MD, Larry Scher, MD, Marc Schermerhorn, MD, Murray L. Shames, MD, Niten Singh, MD, Frank J. Veith, MD, Robert Eugene Zierler, MD Resident/Fellow Editor Christopher Audu, MD Executive Director SVS Kenneth M. Slaw, PhD Director of Membership, Marketing and Communications Tara J. Spiess, CAE Managing Editor SVS Beth Bales Marketing & Membership Specialist Amber Dunlop Assistant Marketing & Social Media Manager Kristin Crowe

2 | Vascular Specialist

about potentially important work- or organization-related issues from persons who might be able to take action to address those issues.”2 There is obviously some nuance to this, rather than a binary choice. Benign examples of silence include new hires choosing to be silent in order to scan the workplace and, with time, evolve into a voice. Experienced hires may start as a voice but, either from bad experiences associated with career derailment or fatigue based on learned helplessness (lack of response for change) may choose to stay silent. Also, physicians may be a voice on some and adopt silence on other issues. Furthermore, because one is a voice in meetings does not mean that person does not have hidden feelings and, similarly, the quiet physician does not necessarily imply that that physician has hidden issues they are holding inside. In addition to individual or intrinsic factors, silence may be self-imposed due to extrinsic factors. Some of us may resent being under pressure to stay silent in order to avoid personal harm, and take on passive-aggressive behavior by being a voice on easy, non-controversial issues, but withhold important and critical information from leaders.

Reasons for this self-imposed silence may be several, but primarily because it represents a danger in some way, or is seen as pointless. Job security, academic promotion, or moving up in a professional society may lead to internal pressure to inhibit expression and modify behavior, which then takes a psychological toll on the physician—especially in a personality that wants to progress but does not like making “waves.”

Is there a link between silence, psychological safety and burnout? Apparently, yes. Knol indicates that it is frequent silence, particularly “high silence” (suppression of serious flaws), that engenders burnout rather than voice reducing

Bhagwan Satiani

Is there a link between silence, psychologic safety, and burnout? Apparently yes it.1 Sherf and colleagues contend that we rely on our biologically based intrinsic “behavioral activation system” and “behavioral inhibition regulatory system” to assist us on when we use our voice or silence.3 The former is more of a positive state of mind and hopeful, whereas the latter is concerned with the worry, even threats, from speaking out. They also point out that individual personality traits— such as extroversion for instance—may affect outcomes.

Having had experience in both the private sector as well as the academic workplace, I have observed that the latter physician is more prone to suffer burnout from pressure to remain silent, probably because one expects to express one’s thoughts and ideas freely in the learning environment. I have seen senior faculty fear for their job and career advancement if they were to speak out and displease a chair or a dean. This forced silence then becomes incorporated into the culture as younger folks watch and learn that they do not have the freedom to continued on page 4

Vascular Specialist is the official newspaper of the Society for Vascular Surgery and provides the vascular specialist with timely and relevant news and commentary about clinical developments and about the impact of healthcare policy. Content for Vascular Specialist is provided by BIBA Publishing. Content for the News From SVS is provided by the Society for Vascular Surgery.

POSTMASTER: Send changes of address (with old mailing label) to Vascular Specialist, Subscription Services, 9400 W. Higgins Road, Suite 315, Rosemont, IL 60018.

The ideas and opinions expressed in Vascular Specialist do not necessarily reflect those of the Society or the Publisher. The Society for Vascular Surgery and BIBA Publishing will not assume responsibility for damages, loss, or claims of any kind arising from or related to the information contained in this publication, including any claims related to the products, drugs, or services, or the quality or endorsement of advertised products or services, mentioned herein.

For missing issue claims, e-mail subscriptions@bibamedical.com.

The Society for Vascular Surgery headquarters is located at 9400 W. Higgins Road, Suite 315, Rosemont, IL 60018.

RECIPIENT: To change your address, e-mail subscriptions@bibamedical.com.

Vascular Specialist (ISSN 1558-0148) is published monthly for the Society for Vascular Surgery by BIBA Publishing.

Published by BIBA Publishing, which is a subsidiary of BIBA Medical Ltd. Publisher Roger Greenhalgh Content Director Urmila Kerslake Managing Editor Bryan Kay bryan@bibamedical.com Editorial contribution Jocelyn Hudson, Will Date, Jamie Bell, Sarah Croft, Anthony Strzalek and Aaron Kudhail Design Terry Hawes Advertising Nicole Schmitz nicole@bibamedical.com Letters to the editor vascularspecialist@vascularsociety.org

Printed by Vomela Commercial Group BIBA Medical, Europe 526 Fulham Road, London SW6 5NR, United Kingdom

©Copyright 2022 by the Society for Vascular Surgery

BIBA Medical, North America 155 North Wacker Drive – Suite 4250, Chicago, IL 60606, USA

February 2022

GUEST EDITORIAL

Silence is golden— but does selfimposed silence lead to burnout? continued from page 2

dissent. Among other stressors, inability to express ideas at work is a recipe for burnout.

One could blame the general erosion of free speech, but this facet existed long before current trends.

Why is this important for hospital leaders?

Leaders may not be aware that they are suppressing employee voices and fostering silence, because high silence in a health system is not only related to exhaustion and burnout, but hurts productivity. It also harms patient care in the safety and quality-of-care sphere.

Leaders are also trying to combat burnout using all the tools they have but may remain non-cognizant of the link between silence and burnout. Instead, their way of addressing burnout is of a transactional nature.

How does the leader provide psychological safety to physicians and other employees and assure their well-being? Psychological safety is described as ‘‘the degree to which people view (their) environment as conducive to interpersonally risky behaviors like speaking up or asking for help.”4 Establishing psychological safety has to be part of a cascading organizational culture. In the non-clinical areas, leaders should allow, support and commend physicians to take risks by sharing information and ideas, asking

questions, offering feedback and airing concerns.

Anonymous surveys that do not ask for demographic data, may allow frank input.

While supportive voices are given more weight by leaders and managers, giving physicians space to freely share their thoughts and ideas in a safe manner needs to be emphasized. Besides the resilience, as well as mindfulness training, tips on communication skills that include techniques to express thoughts in a non-threatening manner may also be useful.

Ultimately, our leaders need to be encouraged to allow respectful dissent and discussion under the umbrella of psychological safety for physician employees. Self-imposed silence is an important stressor for burnout.

References 1. K noll M, Hall RJ, Weigelt O. A longitudinal study of the relationships between four differentially motivated forms of employee silence and burnout. Journal of Occupational Health Psychology. 2018; 24(5), 572–589.

2. Morrison, E. W. Employee voice behavior: Integration and directions for future research. The Academy of Management Annals. 2011; 5(1), 373–412.

3. Sherf EN, Parke MR, Isaakyan, S. Distinguishing voice and silence at work: Unique relationships with perceived impact, psychological safety, and burnout. Academy of Management Journal. 2021; Vol. 64, No. 1, 114–148.

4. Edmondson AC, Higgins M, Singer S, et al.

Understanding psychological safety in health care and education organizations: A comparative perspective. Res Hum Dev. 2016; 13:65–83.

BHAGWAN SATIANI is professor emeritus in the division of vascular diseases and surgery in the College of Medicine at The Ohio State University, Columbus, Ohio. He is an associate medical editor of Vascular Specialist.

Marston: Diversity required to deliver comprehensive care to vascular disease population WILLIAM A. MARSTON, MD, WAS RECALLING A recent experience acting as a bone marrow donor for a family member, and the moment it dawned on him, after the harvesting procedure with a specialist in the field, the true value of the knowledge, skill and training it takes to make the routine routine in his own vascular domain. “In our world, this is devalued,” said the vascular William A. surgery division chief at the University of North Carolina Marston at Chapel Hill. He was addressing the 2022 Southern Association for Vascular Surgery (SAVS) annual meeting ( Jan. 19–22) in Manalapan, Florida, his swansong as SAVS president. “These procedures are life and limb saving,” he told attendees. “The things that we do, we do them every day—but we don’t internalize or appreciate it.”

Marston provided a prescription for his peers struggling to fully appreciate what it is they do day after day. “Take satisfaction in providing good patient care, even if it’s not procedural. If you advise someone not to have a procedure, that may sometimes be the best thing that you could do,” he said.

“Support your peers, talk to each other; we all have complications, be realistic about them.” Beware comparing yourself to podium experts, Marston said.

“Most of us are experts in little, narrow things. When we talk about some great case we did, for me it might be a vena cava reconstruction. But I don’t do complex aneurysms with Mark Farber around. I don’t do retrograde pedal access. So, if you’re treating a broad selection of vascular patients, do a good job, do the best techniques you can and sleep well with it.”

He titled his address around the concept of the vascular surgeon and what might be “the right stuff ” for specialists—a play on the eponymous 1980s movie about the pioneering days of the U.S. space development program and the space race’s symmetry with the swashbuckling gestation period of the vascular surgical specialty. “In the movie,” Marston said, “astronauts competed to be the first; they all wanted to be the first in space, and that had to be the best one. But I believe that today, in 2022, the right stuff should be defined by the collective success of a program to provide focused care for the largest population of patients with vascular disease possible. To achieve this, we need vascular surgeons of all backgrounds, all races, all ethnicities with the diversity to deliver care to all patients with vascular disease.”—Bryan Kay

Endurant™ II/Endurant™ IIs Stent Graft

Indications: The Endurant™ II/Endurant™ IIs bifurcated stent grafts are indicated for the endovascular treatment of infrarenal abdominal aortic or aortoiliac aneurysms. They may be utilized in conjunction with the Heli-FX™ EndoAnchor™ system when augmented radial fixation and/or sealing is required; in particular, in the treatment of abdominal aortic aneurysms with short (≥ 4 mm and < 10 mm) infrarenal necks (see Neck length definition below). The Endurant II stent graft system aorto-uni-iliac (AUI) stent graft is indicated for the endovascular treatment of infrarenal abdominal aortic or aortoiliac aneurysms in patients whose anatomy does not allow the use of a bifurcated stent graft. The Endurant II/IIs stent graft system is indicated for use in patients with the following characteristics: • Adequate iliac or femoral access that is compatible with vascular access techniques, devices, or accessories • Proximal neck length of • ≥ 10 mm; or • ≥ 4 mm and < 10 mm when used in conjunction with the Heli-FX EndoAnchor system (bifurcated stent graft only) Note: Neck length is defined as the length over which the aortic diameter remains within 10% of the infrarenal diameter. • Infrarenal neck angulation of ≤ 60° • Aortic neck diameters with a range of 19 to 32 mm • Distal fixation length(s) of ≥ 15 mm • Iliac diameters with a range of 8 to 25 mm • Morphology suitable for aneurysm repair Contraindications: The Endurant II/Endurant IIs stent graft system is contraindicated in: • patients who have a condition that threatens to infect the graft • patients with known sensitivities or allergies to the device materials When used with the Heli-FX EndoAnchor system, the Endurant II/IIs stent graft system is also contraindicated in: • patients with known sensitivities to the EndoAnchor implant materials. For contraindications regarding ancillary devices used with the Endurant II/Endurant IIs stent graft system, refer to the Instructions for Use provided with the device.

Warnings and Precautions: • The long-term safety and effectiveness of the Endurant II/Endurant IIs stent graft system has not been established. All patients should be advised that endovascular treatment requires lifelong, regular follow-up to assess the health and the performance of the implanted endovascular stent graft. Patients with specific clinical findings (e.g., endoleaks, enlarging aneurysms, changes in the structure or position of the endovascular graft), or less than the recommended number of EndoAnchor implants when used in short proximal necks (≥ 4 mm and < 10 mm), should receive enhanced follow-up. Specific follow-up guidelines are described in the Instructions for Use. • Patients experiencing reduced blood flow through the graft limb, aneurysm expansion, and persistent endoleaks may be required to undergo secondary interventions or surgical procedures. • The Endurant II/Endurant IIs stent graft system is not recommended in patients unable to undergo or who will not be compliant with the necessary preoperative and postoperative imaging and implantation procedures as described in the Instructions for Use. • Renal complications may occur: 1) From an excess use of contrast agents. 2) As a result of emboli or a misplaced stent graft. The radiopaque marker along the edge of the stent graft should be aligned immediately below the lower-most renal arterial origin. • Studies indicate that the danger of micro-embolization increases with increased procedure duration. • The safety and effectiveness of the Endurant II/ Endurant IIs stent graft system has not been evaluated in some patient populations. Please refer to the product Instructions for Use for details.

MRI Safety and Compatibility: Non-clinical testing has demonstrated that the Endurant II/Endurant IIs stent graft is MR Conditional. It can be scanned safely in both 1.5T & 3.0T MR systems under certain conditions as described in the product Instructions for Use. For additional MRI safety information, please refer to the product Instructions for Use. Adverse Events: Potential adverse events include (arranged in alphabetical order): amputation; anesthetic complications and subsequent attendant problems (e.g., aspiration), aneurysm enlargement; aneurysm rupture and death; aortic damage, including perforation, dissection, bleeding, rupture and death; arterial or venous thrombosis and/or pseudoaneurysm; arteriovenous fistula; bleeding, hematoma or coagulopathy; bowel complications (e.g., ileus, transient ischemia, infarction, necrosis); cardiac complications and subsequent attendant problems (e.g., arrhythmia, myocardial infarction, congestive heart failure, hypotension, hypertension); claudication (e.g., buttock, lower limb); death; edema; EndoAnchor system (for infrarenal EVAR procedures using the Heli-FX EndoAnchor system): partial deployment, inaccurate deployment, fracture, dislodgement, embolization, stent graft damage, modelling balloon damage); embolization (micro and macro) with transient or permanent ischemia or infarction; endoleak; fever and localized inflammation; genitourinary complications and subsequent attendant problems (e.g., ischemia, erosion, femoral-femoral artery thrombosis, fistula, incontinence, hematuria, infection); hepatic failure; impotence; infection of the aneurysm, device access site, including abscess formation, transient fever and pain; lymphatic complications and subsequent attendant problems (e.g., lymph fistula); neurologic local or systemic complications and subsequent attendant problems (e.g., confusion, stroke, transient ischemic attack, paraplegia, paraparesis, paralysis); occlusion of device or native vessel; pulmonary complications and subsequent attendant problems; renal complications and subsequent attendant problems (e.g., artery occlusion, contrast toxicity, insufficiency, failure); stent graft: improper component placement; incomplete component deployment; component migration; suture break; occlusion; infection; stent fracture; graft twisting and/ or kinking; insertion and removal difficulties; graft material wear; dilatation; erosion; puncture and perigraft flow; surgical conversion to open repair; vascular access site complications, including infection, pain, hematoma, pseudoaneurysm, arteriovenous fistula, dissection; vascular spasm or vascular trauma (e.g., iliofemoral vessel dissection, bleeding, rupture, death); vessel damage; wound complications and subsequent attendant problems (e.g., dehiscence, infection, hematoma, seroma, cellulitis). Please reference product Instructions for Use for more information regarding indications, warnings, precautions, contraindications and adverse events.

CAUTION: Federal (USA) law restricts this device to sale by or on the order of a physician.

medtronic.com/aortic UC202210505 EN © 2021 Medtronic. All rights reserved. Medtronic, and Medtronic logo are trademarks of Medtronic. ™ *Third party brands are trademarks of their respective owners. All other brands are trademarks of a Medtronic company.

For distribution in the USA only. 11/2021

4 | Vascular Specialist

February 2022

INTERVIEW

Radiation protection: Lightweight shield designed to reduce eye, brain dose during complex endovascular procedures gains ground

BY SARAH CROFT

It all started with a “we should do research together; this is fascinating.” The result— the production of a prototype eyewear that decreases radiation to the eye and brain—is the more-than-decade-long toil of Melissa Kirkwood, MD, and colleagues at UT Southwestern in Dallas, Texas. From conference podium to conference podium, through endless research studies and paper-writing, Kirkwood has put in the miles to get the disposable, lightweight shield patented. Here, the UT Southwestern vascular chief tells Vascular Specialist about her journey and production of the “much-needed” device aimed at helping surgeons and interventionalists combat radiation exposure.

VS: Can you give an overview of your research journey in radiation safety so far?

MK: Yes, about 11 years ago our vascular division was flagged for having a high radiation dose case. It involved a physician modified aortic stent graft in a morbidly obese patient. Because of this, our radiation physicists had to come and speak with us as a group. I was fascinated by the topic and what they were discussing.

There are so many simple things that we can do to decrease our radiation dose. After this talk with the physicists, I went up to Dr. Gary Arbique and Dr. Jeffrey Guild and said, “We should do research together; this is fascinating.” Our first project was simply looking at the radiation dose from our complex cases before and after our talk with the physicists, during which we learned some tricks to decrease dose. After controlling for multiple factors, we were able to show that by implementing simple things, you can significantly drop the radiation dose. We then looked at the risk of deterministic effects, namely skin injuries in patients following high radiation dose cases. We studied this initially retrospectively. We then started a prospective study following these patients with skin exams. What we found was skin injuries are extremely rare and are likely multifactorial, with some patient predisposing factors and not solely based on dose.

Then we progressed and looked deeper, specifically at surgeon dose. We found that factors like where the surgeon stands around the table, whether the tablemounted lead skirt is utilized, and what type of case is performed matter significantly. This paper showed that fenestrated endovascular aortic repairs (FEVARs) are by far the highest dose cases that we perform as vascular surgeons, so then we took a deeper dive looking only at FEVARs. We showed that not all FEVARs are equal in dose, and that custom-made devices require more dose than pre-manufactured devices, and the number of vessel fenestrations is a driver of increased dose. After this study, we focused on additional adjuncts to lower dose during FEVARs, such as using dual fluoroscopy with live digital zoom instead of magnification modes; employing a two-dimensional vessel navigator roadmap instead of an on-table 3D CT; and ensuring all equipment is up to date on new dose-lowering software.

Most recently, we have been focusing on what does not work for radiation. We have shown that the no-brainer surgical caps and regular leaded caps do not decrease

6 | Vascular Specialist

perfecting the design and have created a prototype, which is patented at UT Southwestern Medical Center. The eyewear attachment has been proven to decrease both eye and brain dose to the operator, and works equally well added to leaded or non-leaded routine prescription eyewear. This was recently presented at the 2021 Western Vascular Society (WVS) annual meeting.

VS: What more can you tell us about the latest data?

MK:. In this study, we have shown that when this prototype is added to leaded or non-leaded glasses, the dose to the lens, temporal lobe and midbrain is reduced by 85%, 81% and 71%, respectively. This means that interventionalists do not have to buy and wear leaded lenses anymore.

Our prototype is just as effective when added to plastic safety glasses or prescription eyewear. The device is lightweight, detachable and reversible, so it can be used for either the right or left eye/face. Only the eye that is closest to the X-ray source needs coverage. The prototype has a sleeve for the temples of the eyewear, and then the shield is molded around the operator’s face and the inferior aspect of the lenses by a conformable wire. The adhesive strip attaches to the surgical mask, eliminating any air gap between the lower face and the eyewear. It is made of lead-equivalent shielding sewn into soft cloth material. Even though it is disposable, it is not necessarily single use. I have worn it in multiple procedures without any decrease in efficacy. And the best part is, it is comfortable and there is no fogging.

We are really excited about this shield because it is an easy adjunct that can be incorporated into daily practice to Melissa improve safety. When the Kirkwood interventionalist goes to grab his or her hat, mask, and shoe covers, that is when to grab the eye/face shield too.

VS: Do you think your findings will change future practice?

This shield is something that should be added to the operating room routine when you are grabbing your mask and eyewear protection brain radiation at all, because the radiation that hits the head is from scatter radiation already attenuated through the patient and not hitting the head at 90-degree angles.

After discovering this we questioned the effectiveness of leaded eyewear. Sure enough, we proved that leaded eyewear does not decrease eye dose at all due to the significant air gap between the face and the leaded lens.

The leaded lens can only attenuate direct X-rays to the eyes, and since all the scatter is from the patient hitting the interventionalist at angles not covered by the glasses, they are completely ineffective.

However, this seemed like a solvable problem. Our first attempt at this was studying the efficacy of adding leaded shielding to the lateral and inferior aspect of the glasses. This was a success. Closing the air gap between the operator’s face and their eyes significantly decreased eye dose. But this design was heavy, uncomfortable and caused fogging. Therefore, we have been working on

MK: I hope so. Many reports have shown an increased prevalence of radiation-induced lens damage (cataracts) and brain cancer in interventionalists. The International Commission on Radiological Protection (ICRP) has set the occupational dose limit to the lens of the eye at a 20 mSv/year average over five years, with no annual dose in a single year exceeding 50mSv. Thus, the results from this study have shown that with the addition of our prototype, operators can safely perform exponentially more cases and still stay under the aforementioned ocular dose threshold. We strongly believe that our design can help mitigate some of the long-term health complications that interventionalists can experience, and hope that using our eye/face shield becomes standard practice to improve safety.

VS: Have there been any other recent developments?

MK: Not on this study, but we did just present at the 2022 Southern Association for Vascular Surgery (SAVS) annual meeting on the efficacy of lower-leg leaded garments in decreasing lower-body radiation dose during FEVARs. We also presented some new data on the CLEAR-MAX imaging technology system and how it lowers radiation dose on Siemens systems. Next steps are working with UT Southwestern to find a commercialization partner to bring the product to market. Stay tuned!

February 2022

THIS ADVERTORIAL IS SPONSORED BY GORE

How an aortic ally can help physicians optimize patient outcomes

BY KIMBERLEY WUNDER, PHD

The aorta is special. As one of the most complex and critically important vessels of the vascular system, the aorta presents unique challenges. As such, it deserves an investment in constant and specialized care to ensure optimal patient outcomes.

I’VE OFTEN HEARD THE QUESTION “What is the device manufacturer’s role beyond providing products?”

Clinicians benefit greatly from a device manufacturer relationship that provides much-needed clarity on recommended solutions for their patient. From highly responsive device delivery, to deeply specialized technical expertise, to complete consultative discussions, physicians need to know they can count on their medical device provider as a source of integral support. Physicians need an aortic ally who is equally invested in achieving the best possible outcomes for patients.

Whether a vascular or cardiothoracic surgeon is performing an endovascular aneurysm repair (EVAR) or thoracic EVAR (TEVAR) procedure, they need to feel they can trust and rely on the device, as well as the manufacturer’s clinical and

technical knowledge that support the use of that device.

For example, a trusted aortic ally supports the physician Kimberley Wunder well beyond the acquisition of a product, providing technical expertise for their device of interest and supporting clinical decision-making by sharing their knowledge of clinical trials and outcomes.

What type of experience and knowledge does the clinical or sales representative offer? How many cases do they support on average? They should be able to rely on their aortic ally for timely responses, trusted information, and essential technical device proficiency for EVAR and TEVAR procedures, literature case studies, and device specificity for unique anatomies and cases.

“How does a medical device manufacturer evolve to demonstrate commitment to innovation and valuable experiences to provide the best outcomes for patients?”

How does a medical device manufacturer evolve to demonstrate commitment to innovation and valuable experiences to provide the best outcomes for patients? A good aortic ally is committed to the development, support and refinement of physician-supportive resources. Such resources include case studies and educational webinars to share

surgical expertise, thought leadership on cutting-edge research, clinical trial developments, and the latest product innovations, demonstrations and videos of device use, product information and literature, and peer recommended techniques. This array of supporting resources should be simple to navigate, have practical application, and be succinct and easy to share with physician peers.

In today’s fast-moving surgical landscape, this means device manufacturer support that goes beyond products and considers holistic solutions that can be tailored to different types of patients. Equally important is an understanding of aortic device limitations in critical cases. A device manufacturer committed to the best patient outcomes includes a sales force with a focus on supporting physicians in choosing the right product for each patient, even when that product is not their own.

Ultimately, an aortic ally combines innovation with reliability for solutions that deliver real-world improvements to the lives of patients with aortic disease.

Visit goremedical.com/aorticsupport to find out how an aortic ally can help you.

KIMBERLEY WUNDER is a Clinical Application Specialist at W. L. Gore & Associates, delivering clinical and operational expertise, and providing education and training support within the aortic product portfolio to clinical end-users. She is passionate about engaging with customers, and accelerating research and development efforts into improved clinical outcomes.

February 2022

vascularspecialistonline.com | 7

COMPLEX TAAA

COVER STORY

US ARC IDE registry reports better survival vs. real-world data after endovascular repair continued from page 1

Results from the consortium’s retrospective analysis of U.S. ARC and VQI procedures carried out between 2011–2019 were delivered by Ryan Heslin, BS, a medical student at the University of South Alabama College of Medicine in Birmingham, Alabama, with senior author Adam Beck, MD, vascular division director at the University of Alabama at Birmingham and one of the IDE investigators, present as a moderator of the scientific session in which the paper featured.

The research team aimed to compare the real-world setting of the Society for Vascular Surgery (SVS) VQI database to that of the now 10-strong physician-sponsored U.S. ARC trials in order to evaluate the effect of custom-built or off-theshelf fenestrated/branched endovascular devices. Despite the fact there are no commercially available devices for the repair of TAAAs in the U.S., an increasing number of patients are felt to be at high risk for open repair and are therefore undergoing endovascular repair, Heslin noted.

“These data are collected in the SVS VQI registry,” he said.

“The U.S. Aortic Research Consortium has access to these custom-built branched/fenestrated endovascular devices that are designed to match patients and are not present in the VQI.” The analysis of 3,212 patients—all of whom underwent elective procedures for asymptomatic, non-ruptured aneurysms, and had defined zones of endograft

deployment—showed a 30-day mortality rate of 6.1% in the VQI vs. 2% in the U.S. ARC for Crawford classification system extent 4 TAAAs. At one year, the equivalent rates were 12.3% (VQI) vs. 8.4% (ARC). Similarly, 30-day and one-year mortality in the cases of extent 1–3 and 5 aneurysms were 7.3% (VQI) vs. 2.6% (ARC), and 16.3% vs. 13.1%, respectively.

“The appearance of our Kaplan Meier survival curves mostly mirror our findings at 30 days and one year, with a significant drop off in the perioperative period for the VQI group, but a significant difference in survival was noted in both groups,” Heslin added.

“Patients repaired in the IDE studies have better perioperative and one-year survival compared to patients treated off label or entered in a real-world registry, regardless of extent” Ryan Heslin Commenting on the idiosyncracies two registries, Heslin explained that though the patient populations studied are similar in terms of pathology, “the conditions under which they are studied are quite different.” He continued: “The VQI represents real-world practice using off-label techniques, including physician-modified grafts [PMEGs] and parallelstenting techniques. This dataset allows us to evaluate endovascular techniques outside of clinical trial settings, and thus is much more representative of the general population.

“The U.S. ARC is a group of investigators with physiciansponsored IDEs that has access to endovascular repair using custom-built or off-the-shelf medical devices. This allows us to evaluate the outcomes of endovascular repair in a clinical

trial setting. It is important to know these patients are highly selected for and studies are under heavy scrutiny from multiple avenues.” Heslin pointed out that the researchers had elected to study Crawford extent 4 aneurysms separately from extents 1–3 and 5 mostly because of overall volume, their lack of a thoracic component, and differences in overall management.

Notable differences among extent 4 patients in the U.S. ARC population included the fact they were more often Caucasian, male and in possession of a history of coronary artery disease (CAD), he said. The VQI equivalent patients more commonly had a history of chronic obstructive pulmonary disease (COPD) and diabetes. Those with extent 1–3 and 5 aneurysms in the ARC dataset were more likely to be older by about a year, Caucasian, and have a history of CAD. Their VQI counterparts were more likely to have a history of congestive heart failure and COPD. “It is important to note that maximal aneurysm diameter did not vary across the VQI or ARC datasets in any Crawford extent,” said Heslin.

He conceded certain limitations to the study. “We did not evaluate risk-adjusted mortality,” he began. “While patients overall had similar comorbidities, disease-specific death was not used to compare overall survival. We believe that risk adjusting this type of analysis removes the clinical decisionmaking that is critical in these elective procedures in complex aneurysms. Additionally, we did not evaluate long-term mortality after one year. We believe that 30-day mortality likely represents procedural success in patient selection, and one-year mortality is indicative more specifically of patient selection.

“Although reintervention and device or aortic failures may impact longer-term survival, this is likely more impacted by patient factors such as age and comorbidities, as well as unmeasured outcomes such as cancer-related deaths. In summary, in both the ARC and VQI cohorts, more extensive

Aortic Research Consortium ‘pushes the envelope’ on F/BEVAR

BY JOCELYN HUDSON

The U.S. investigational device exemption (IDE) Aortic Research Consortium (ARC) has produced the strongest data so far on the use of fenestrated/branched endovascular aneurysm repair (F/ BEVAR), Andres Schanzer, MD, professor and chief of vascular surgery at the University of Massachusetts Medical School in Worcester, Massachusetts, claimed at the Critical Issues in Aortic Endografting 2021 meeting (Dec. 17–18) in Paris, France. As a result of the group’s work, “more patients are getting better care, by more providers, using F/BEVAR devices,” he said, summarizing a slew of data unveiled since 2018.

T

he primary objective of the ARC, first conceived of in 2018, is to evaluate custom-made fenestrated and branched endovascular devices for the treatment of patients with complex abdominal, thoracoabdominal and arch aneurysms, Schanzer detailed.

He noted that, currently, the literature includes primarily iterative, single-center reports, the findings of which “may be limited due to the potential for a type 1 error secondary to limited statistical power.” According to Schanzer, ARC medical director, that is about to change, 8 | Vascular Specialist

as the consortium includes prospective, physician-sponsored data from across 10 U.S. sites and is independently monitored and Food and Drug Administration (FDA) audited. Referencing an email he sent to investigators when initiating this effort in early 2018, Schanzer wrote: “If we are able to pull this off and figure out a way to aggregate our data in a relatively seamless way and work together as a team of investigators, I believe we have the potential to make a much more significant impact than multiple iterative, single-center reports.”

Andres Schanzer

Key datasets highlight growing pool of evidence Members of the U.S. F/BEVAR ARC have presented data on behalf of the consortium at several key conferences since 2018.

The datasets started off small, Schanzer relayed. At the Society for Vascular Surgery (SVS) 2018 Vascular Annual Meeting (VAM) in Boston, for example, Emanuel R. Tenorio, MD, a postdoctoral researcher at the University of Texas Health Science Center at Houston in Houston, Texas, presented outcomes of endovascular repair of post-dissection and degenerative thoracoabdominal aortic aneurysms (TAAAs) using fenestrated and branched stent grafts. The study,

which incorporated 240 patients, showed F/BEVAR to be safe and effective, with similar outcomes in patients with postdissection and degenerative TAAAs, and also that patients with post-dissection had more type II endoleak during follow-up.

Tenorio stressed that larger clinical experience and longer follow-up was needed to better evaluate differences in mortality, spinal cord injury, target vessel instability and secondary interventions.

At the same meeting, Schanzer recounted, Darren B. Schneider, MD, chief of vascular surgery and endovascular therapy at the University of Pennsylvania, Philadelphia, presented target artery outcomes after branched and fenestrated February 2022

aneurysms, extents 1, 2, 3 and 5, have poorer survival at 30 days and one year. Survival at 30 days and one year was statistically better for ARC patients in both groups.”

The challenges faced in repairing TAAAs with endovascular devices has bred brisk surgeon activity in the arena, Heslin commented.

“Limitations of endovascular repair have largely been challenges related to the inclusion of aortic branches, thus patients needed to be anatomically suitable for optimal repair,” he said. “This problem has inspired numerous and creative ways that vascular surgeons have continued to approach thoracoabdominal aneurysm repair, including PMEGs, parallel-stenting grafts and other techniques, and most-recently custom or purpose-built endografts designed to specifically match patient anatomy.”

That’s where the IDE trials come in.

Concluding, Heslin highlighted that the IDE trial patients studied had better perioperative and one-year survival compared to patients treated off label or entered in a real-world registry, regardless of extent.

“The reasons for these differences require further analysis and remain unclear,” he said. “A couple of things they could be related to would be differences in devices or device durability, differences in device comorbidity profiles, the intangible surgeon and patient psychosocial factors related to when, whether and how to repair these aneurysms, as well as volume-related outcomes. All of these IDE centers have dedicated teams of research coordinators and nurses. These include dedicated resources and additional infrastructure that help manage those patients. This allows for a more programmatic approach to each patient, which likely contributes to better outcomes.”

Designated discussant Michol A. Cooper, MD, an assistant professor in the division of vascular surgery and endovascular therapy at the University of Florida College of Medicine in Gainesville, Florida, asked for further comment on the survival curves, saying: “Although the overall mortality for the VQI is greater for patients in both groups, based on the Kaplan Meier curves, the

endovascular repair of pararenal aortic aneurysms and TAAAs in 661 patients.

Schneider summarized that the selective use of fenestrations and directional branches for visceral artery incorporation is durable, that the risk of target artery instability is higher for renal versus mesenteric arteries, and that greater TAAA extent is associated with increased target instability.

Future efforts, he informed the VAM 2018 audience, should focus on improving renal artery patency and reducing interventions.

Later that same year, Schanzer recalled that Carlos H. Timaran, MD, the Sam H. Phillips, Jr. MD Distinguished Chair in Surgery at University of Texas Southwestern, Dallas, Texas, gave evidence on the expanded use of preloaded branches and fenestrated endografts for endovascular repair of complex aortic aneurysms.

Speaking at the 32nd European Society for Vascular Surgery (ESVS) Annual Meeting in Valencia, Spain, Timaran presented data on 564 patients, concluding that the expanded use of preloaded catheters and wires of fenestrations and directional branches for target artery incorporation is associated with even higher technical success and lower early mortality.

Schanzer then looked back to the 2019 VAM in National Harbor, Maryland, where he presented results of F/BEVAR after failed infrarenal EVAR in 893 patients. He noted that F/BEVAR was safe and effective in patients with prior failed EVAR, with February 2022

majority of the difference appears to be in the initial postoperative period, after which the mortality curves parallel each other.”

Heslin pondered several possibilities associated with a “really high” relative risk of perioperative mortality. “We discussed patient selection and procedural success previously, which we believe certainly could play a role. Additionally, it could be related to a high-volume center. You could have staff and nurses and dedicated teams, like there is in the IDEs, that are much more comfortable managing the complications that may arise. So, successfully managing these perioperative complications may additionally lead to decreased perioperative mortality as well.”

The data also prompted Murray Shames, MD, chief of vascular surgery at the University of South Florida (USF) Health Morsani College of Medicine in Tampa, Florida, to ask Heslin whether “industry has a responsibility to expand access if it is shown that [these] devices are better than what is being done in the real world.” The rest of the world has access to such devices, he said.

“Europe has devices, Asia has devices, Australia has devices, and we are still limited to [the IDE] sites.”

U.S. ARC investigator and session moderator Beck stepped in, arguing that responsibility also falls upon the FDA to expand access. “These things are going to be expanded,” he said. “It is just going to take time. Unfortunately, we may be talking about five or 10 years down the road before these things are available.”

Shames said his institution has two IDE trials of its own—one involving purpose-built and the other PMEG devices. Beck reasoned that PMEG IDEs “would be really interesting to study in addition to the VQI data, which are non-IDE PMEG devices, essentially.” David Minion, MD, a professor of surgery at the University of Kentucky in Lexington, Kentucky, added that specialists faced a reproducibility crisis. “Seventy percent of all studies are not reproducible.­” He wondered whether the right question was being asked: “Is it getting more access to more centers? How do we deal with that crisis of being able to compare these things?”—Bryan Kay

nearly identical outcomes as compared to patients without prior EVAR, while differences in procedural metrics indicated higher level of technical challenge when performing F/BEVAR in patients with prior failed EVAR. The speaker concluded that F/BEVAR, at high-volume centers, is a viable option for the treatment of EVAR failure that compared favorably to historical reports of open conversion.

“More patients are getting better care, by more providers, using F/BEVAR devices” Andres Schanzer At the 33rd ESVS Annual Meeting in Hamburg, Germany, in 2019, Fernando Motta, MD, a vascular surgeon at the University of North Carolina, Chapel Hill, North Carolina, informed the audience that F/BEVAR is a safe and effective option for octogenarians in training complex aortic aneurysms compared to nonoctogenarians, Schanzer detailed, outlining data from 893 patients.

Finally, Schanzer gave an overview of the largest U.S. IDE Consortium dataset so far—a study on sex-related outcomes after F/BEVAR for TAAAs involving 1,681 patients. Announcing the findings during ESVS Month in 2020, Matthew P. Sweet, MD, a vascular surgeon at the University of

Washington, Seattle, revealed that women experienced higher rates of technical failure for extensive aneurysms, non-home discharge and postoperative sac expansion.

A turning point for fenestrated and branched procedures Addressing the Critical Issues audience, Schanzer summarized that the U.S. F/ BEVAR ARC is the largest dataset of fenestrated and branched procedures in the world. The consortium involves a core group of investigators “committed to improving patient care and pushing the envelope on endovascular therapies from the aortic valve to the common femoral artery,” he said The consortium is “an engine for exchange of ideas and promotion of F/BEVAR technologies,” the speaker continued, emphasizing his hope that the group’s work will have an impact not just in the U.S. but across the globe.

On a more practical level, Schanzer said, the consortium “offers infrastructure and a more agile regulatory pathway for testing emerging technologies to obtain preliminary data,” and also represents a departure from the heretofore single-center reports.

The project provides a framework in which to conduct randomized trials, Schanzer stressed, noting that the trajectory of F/BEVAR technologies has reached an “inflection point.”

Larger studies will henceforth reveal the direction of travel in this developing field, he added.

More proximal landing zone produces better outcomes for TEVAR of acute TBAD, study finds A review evaluating the results of thoracic endovascular aortic repair (TEVAR) following acute type B aortic dissection (TBAD) suggests most patients have less than 2cm of proximal healthy descending thoracic aorta. In patients treated for complicated acute TBAD, zone 2 TEVAR is associated with a lower need for aortic reintervention and aortic-related adverse events than zone 3 TEVAR, researchers behind the study found.

Further, patients may benefit from a more aggressive proximal landing zone with similar perioperative morbidity when zone 2 TEVAR is done with left subclavian artery revascularization, according to senior author Jean Panneton, MD, chief of vascular surgery at Eastern Virginia Medical School in Norfolk, Virginia. The study was recently published in the Journal of Vascular Surgery (JVS). “TEVAR for the treatment of complicated acute TBAD has been shown to have favorable outcomes compared to both open aortic repair and medical therapy,” he said. However, the optimal approach—including timing, coverage length and landing zone—has yet to be fully elucidated, he added. Panneton and colleagues performed a retrospective chart review, from a single center, of adult patients who underwent TEVAR for complicated acute TBAD within six weeks of diagnosis from January 2008–December 2018.

“The proximity of the primary tear to the origin of the left subclavian artery can make it difficult to achieve a secure 2cm landing zone of healthy aorta without coverage of one of the aortic arch branch vessels. Notably, 90% of our study patients had a less than 2cm proximal landing zone,” said Panneton. “Factors which may contribute to the better outcomes observed for the zone 2 patients may include a landing zone that is further away from the aortic pathology and is more optimal in terms of seal given it is less curved than in zone 3. Additionally, our low rate of retrograde dissection may be related to avoiding proximal endograft oversizing (>10%) and post-deployment balloon molding.” Many technical details must be considered to achieve excellent outcomes in this difficult patient population, said JVS editors.—Paul DiMuzio, MD

vascularspecialistonline.com | 9

COVID-19 IMPACTS

COVER STORY

Vital signs continued from page 1

expense-per-case, vascular surgery nursing labor expenses per-patient-day and total nursing expense per-relativevalue-unit (RVU), uncovering what lead author and Ochsner senior staff surgeon Clayton Brinster, MD, described as “a disturbing story of increasing total nursing expenses.” He pointed to a top line increase over the last nine months of 67% per month in total nursing expenses in the institution’s vascular surgery units. As most health systems operate at slim (0 to +3%) to negative net financial margins, “this is a staggering increase,” Brinster stated.

The results were derived from seven cohorts corresponding to three-month periods dating to the start of the pandemic in March 2020 through November 2021, and compared with the 14-month period preceding the COVID-19 outbreak. The findings build on data, delivered a year ago, showing that the Ochsner vascular division recorded three-month sustained decreases in operative and outpatient clinical volume, as well as a “severe” financial loss, during the initial stages of the pandemic. Delivering the group’s findings at the 2022 Southern Association for Vascular Surgery (SAVS) annual meeting in Manalapan, Florida ( Jan. 19–22), Brinster told attendees traditional determinants of surgical net revenue—such as total cases per month, RVU per month, and Centers for Medicare and Medicaid Services (CMS) case mix index—showed no significant difference when the post-COVID cohorts were compared with the pre-COVID era. Yet, he informed the gathering, they observed a “consistent erosion of vascular surgery margins,” despite consistencies in revenue generation. As the team delved deeper into the data, standardizing against a per-case basis, “we saw a

10 | Vascular Specialist

similarly disturbing trend, with an increase of about 75% “When you consider that nurses incur a disproportionately per vascular surgery case—that’s the increase in nursing high COVID exposure risk, that means subsequent costs alone,” Brinster said. System-wide, nursing labor quarantines and recoveries, requiring the use of mandatory costs in 2021 increased about 200%, or $104 million more sick time,” he said. “That then leads to decreased available than the 2020 number, he noted. “Don’t forget, 2020 was a labor, increased agency usage and increased costs.” pandemic year with elevated nursing costs as well.”

Summing up, Brinster said the pandemic had intensified Brinster and colleagues went further. The pandemic “an evolving nursing labor crisis that has been going on inevitably will lead to about 80 million Americans either for decades,” with the results from the Ochsner study becoming uninsured or seeing their health insurance status demonstrating a “severe erosion of vascular surgery altered, resulting in shifts in the insurance payor mix and profit margin in the presence of dramatically escalating associated distribution, Brinster explained. This, in turn, nursing labor costs, despite consistent revenue generation directly impacts reimbursement, net revenue and profit present throughout the pandemic.” Tackling the problem margin, he said. “When we looked at our own vascular represents a mammoth task, he said. The government surgery payor mix, we saw some shifts during the course has taken action, pledging to invest $1.5 billion in an of the pandemic: the equivalent attempt to combat the nursing increase in the more profitable crisis. “The educational debt of over “Investments should commercial payor is about +5% on 22,000 nurses and nurses assistants average, and the more costly lowerwill be absolved in exchange for a really be focused on reimbursing Medicaid payor is about commitment to work in critically nursing education, training underserved areas affected by the +5%. This likely will offset, but just looking at +5 and +5 does not show pandemic.” and recruitment—and the whole picture, so we wanted Elsewhere, Brinster said, the 2022 established permanently” Medicare to take it a step further in terms of Physician Fee Schedule will Clayton Brinster standardizing our clinical cost data.” support physician practices that rely This led Brinster et al to scrutinize very heavily on nursing support staff, total nursing expense per RVU, which medical assistants and other clinical he described as “perhaps the most accurate standardized staff covered by Medicare, with rates for registered nurses measure of variation of clinical expenses over time.” increasing by 67%.

In this analysis, they demonstrated “a dramatic 55% Ultimately, the plans seem “stopgap”at both the national conglomerate increase” during the COVID era. The RVU and individual health system levels, he argued. The longdimension also served the purpose of making the data term remedy requires institutional, state and national generalizable beyond Ochsner and capable of application programs to alleviate the workforce and financial crises, across the country, he said. Overall, pandemic peaks in Brinster said. “As we struggle to recover from the ongoing the COVID positivity rate in New Orleans was closely pandemic, investments should really be focused on nursing followed by spikes in nursing labor costs that were “almost education, training and recruitment—and established proportional to the degree of positivity,” Brinster observed. permanently,” he concluded.

February 2022

VASCULAR TRAUMA

New data adds to body of evidence highlighting ‘importance’ of vascular surgery in trauma center setting

BY BRYAN KAY

Another study has emerged showing vascular surgery’s heavy intraoperative consult activity in a level 1 trauma center setting, lending further fuel to the “vascular firefighter” analogy.

A

research team that included fourth-year medical student Abigail Hatcher, MS, of Emory University School of Medicine, Atlanta, and study lead Jaime BenarrochGampel, MD, assistant professor of vascular surgery, found that vascular surgery was consulted at a higher rate in both emergent and immediate operative trauma cases than any other surgical subspecialty at Atlanta’s Grady Hospital over a five-year period from 2015–2019.

Hatcher and colleagues noted that the retrospective analysis showed vascular consults ahead of orthopedic surgery and neurosurgery, both of which—unlike vascular surgery—are required in order for an institution to attain American College of Surgeons (ACS) level 1 trauma center certification.

Overall, vascular surgery was the only surgical group to see a statistically significant upward trend in intraoperative consultation over the period, whereas the other top surgical subspecialties did not experience any statistically significant change, Hatcher revealed.

On multivariate analysis, she continued, “immediate trauma operations, younger patients, and those who presented with a severe injury severity score were independently associated with intraoperative vascular surgery consultation.”

The results were presented at the 2022 Southern Association for Vascular Surgery (SAVS) annual meeting in Manalapan, Florida ( Jan. 19–22) by Hatcher, who told delegates the team hopes to expand the study by recruiting other level 1 trauma centers regionally and nationally in order to more broadly analyze consultation rates of surgical subspecialties. “We propose an assessment of the financial impact of vascular surgery’s contribution in trauma centers, and the adequacy of on-call coverage by vascular surgeons,” said Hatcher, who plans to enter general surgery residency on completion of her medical degree. “We recommend a reevaluation of not only ACS but regional and local guidelines and polices to reflect our findings and the importance of vascular surgery in the trauma setting.”

February 2022

Extent of vascular consults vs. other specialties in certain settings

Study development Speaking to Vascular Specialist after presenting the data, Hatcher and Benarroch-Gampel described how their coming together, mentee with mentor, got the research project rolling.

Hatcher’s background interest in healthcare policy and BenarrochGampel’s robust experience of vascular surgery’s need at the coalface of a level 1 trauma center seeded the endeavor.

“We work incredibly well with our trauma peers here, and we get along incredibly well, and I have seen how much we assist them when they need us,” explained Benarroch-Gampel.

Abigail “That brought us to Hatcher the question: vascular surgeons in one of the busiest trauma hospitals in the nation, though we are pretty involved with them, how come we’re not what we call part of the table?

The ACS guidelines for level 1 trauma certification does not require vascular surgery—why not?”

That’s when the team decided they needed to compare vascular surgery’s trauma consult rate with the other surgical subspecialties. As they sifted through the data, they discovered that of 2,265 patients identified, 221 required vascular consultation, which compared with 507 across the other surgical subspecialties combined. Hatcher, Benarroch-Gampel and colleagues further found that in addition to vascular surgery recording the highest rate of intraoperative consultation overall, it also saw the highest rate among consultations on cases classed as “immediate,” or patients taken to the operating room in under 60 mins.

“Abigail did a really good job finding the data because after I saw what it told us, I said, ‘Wow, we actually come out with more than the required subspecialties in emergent cases,’” said Benarroch-Gampel. “And I call them emergent because if you have six hours to fix a problem, you can just send the patient somewhere. But if you have to fix the problem in hours, you better have the

- Immediate trauma operations: 65.6% vs. 38.1% - Penetrating trauma cases: 73.3% vs. 47.9% - Cases at night: 60.6% vs. 51.9% way to fix the problem in hours.”

Armed with such evidence of vascular surgery’s import in the level 1 trauma setting, the Jamie researchers continue Benarrochto mull over how Gampel best the certification anomaly might be rectified. “It takes buyin from not only other vascular surgeons and programs across the country— because this is a nationwide guideline that we’re addressing—but also the individual hospitals and the trauma teams that you’re assisting,” said Hatcher. “It’s not something that is going to happen overnight, but it is an appropriate change to start talking about and working towards.”

In the meantime, it is imperative that vascular surgery continue to provide a high level of assistance in trauma cases when called upon, Benarroch-Gampel said. There are signs of promise, added Hatcher, who noted major changes to the ACS guidelines in the past, suggesting further updates of this nature “are not out of the realm of possibilities.”

Important cog in healthcare wheel The Society for Vascular Surgery (SVS) last year published a document chronicling the value of the modern vascular surgeon to the healthcare system. The report from the SVS Valuation Work Group highlighted the unique mix of medical, open surgical and endovascular skills vascular surgeons provide, along with the critical role they play in a safe operating room

environment. Benarroch-Gampel said the Atlanta studies represents yet another example that can be used to show how important vascular surgeons are to healthcare systems. “In many cases, we are called the firefighters,” he elaborated.

“The value we provide should be highlighted. And the value we provide should be appreciated. Here, it is. We just need to be sure that nationwide this is something where people understand what vascular surgeons provide.”

Benarroch-Gampel said his group previously published data showing that they had seen a rise in their vascular trauma workload—from about 12% to nearly 80%—with good results. “As a society, we need to support that; we need to show that in the vascular trauma field, we are providing a good job compared to other specialties.”

The sresearch team’s attention now turns to getting their latest data published, but Hatcher disclosed that the SAVS meeting room has already yielded interest from senior vascular surgeons about chipping in with data from their own institutions. “They said, ‘We would love to offer our data over the same time period, or a similar time period,’ to see if this is something that they think they’re already experiencing, but they also want to prove, and contribute to a wider dataset.” For Benarroch-Gampel, the question beckons: Are these results isolated to the Atlanta data, or are they occurring across the country? “I personally believe this is nationwide, and not just in one place,” he said. “This is one of the busiest places, with one of the most well-trained trauma surgeon teams, and we still come in and assist when needed.”

vascularspecialistonline.com | 11

DIVERSITY

COMMENTARY

Sex discordance and postoperative outcomes: We should be vigilant of a real disparity in health outcomes

BY KAREN WOO, MD

The recent JAMA Surgery publication “Association of surgeon-patient sex concordance with postoperative outcomes” is a population-based, retrospective cohort study of more than 1 million patients that concluded “sex discordance between surgeons and patients negatively affected outcomes following common procedures.”1 Furthermore, the finding is driven by “worse outcomes among female patients treated by male surgeons.”

M

y initial reaction upon reading these conclusions was: “How can this be possible?”

The scientist in me was certain I could find something(s) in the methodology that could easily explain how they got these seemingly outrageous findings. Thus, I set off to meticulously review the article.

The authors used the Ontario Health Insurance Plan database, derived from the single government payer for Ontario, Canada. The strength of this dataset is that it is representative of the population of Ontario, more so than most administrative databases available in the U.S., such as Medicare claims, which all have some limitation in the population captured. The authors linked the database to four other databases that provided follow-up data for hospitalizations, emergency department visits, patient demographic information and surgeon level data.

This looked like about as strong a dataset as you could get in the world of “big data.”

The investigators then imposed a number of inclusion criteria that I won’t bore you with. Suffice it to say, I was satisfied that they carefully considered situations that could represent data entry errors (e.g. date of death preceded date of surgery) or could skew the data (e.g. multiple surgical procedures in the same day and sex-specific procedures). These cases were excluded, leaving the authors with 1,320,108 unique patients—an impressive sample size.

Well, what about the statistical methods? I thought surely I could find something to pick apart there. The methods described in detail the sophisticated statistics used (multivariable generalized estimating equation with an independent correlation structure and clustering on the procedure performed). The investigators appeared to have accounted for all the covariates and potential confounders they could in their statistical modeling with the available data. I found myself commending the authors for their appropriate, rigorous and robust statistical approach.

“Big data” analyses such as this are often criticized for being “fishing expeditions,” where the investigators do not start out with a hypothesis

12 | Vascular Specialist

and then perform hundreds of comparisons looking for anything that might be statistically significant and then assign it meaning. Wallis and colleagues were careful to indicate throughout the manuscript that this was not a “fishing expedition.” They presented the preliminary data to support their explicitly stated hypothesis which was that “sex discordance between surgeons and patients may contribute to differences in postoperative outcomes, with worse outcomes in female patients treated by male surgeons.” They carefully outlined the “pre-planned” stratified and subgroup analyses in the methods.

The primary outcome was a composite of death, readmission or major complication (e.g. acute renal failure, stroke, myocardial infarction) within 30 days

‘Big data’ analyses such as this are often criticized for being ‘fishing expeditions’

acknowledged that case complexity could contribute to the findings if male surgeons perform more highrisk cases. The authors did perform an analysis of low- vs high-risk cases, and found that the association of discordance with the primary outcome was robust to this analysis. However, low-risk was defined as appendectomy, cholecystectomy and carpal tunnel release. All other operations were defined as high-risk.

Relevant to vascular surgery, femoropopliteal bypass and abdominal aortic aneurysm (AAA) repair were categorized as high risk. Clearly, within each of those operations, there are complexities such as redo bypass, or short angulated AAA neck, that cannot be captured by administrative data.

Nevertheless, my mind shifted to thinking, “Maybe they have something here.” The only thing these kinds of “big data” analyses can do is demonstrate an association.

It is simply not possible to prove causality using a retrospective cohort study design. In a retrospective study, it is entirely possible for two variables to be associated with each other without one causing the other. That said, the investigators did a good enough job with this study for me to believe the observed association in this dataset was real. The obvious next question was “What is the underlying cause?” The authors speculated in the discussion that these findings may be a result of the way sex discordance between surgeon and patient may “adversely affect the physician-patient relationship.”

There are abundant data, although largely in medical specialties, to demonstrate that the physician-patient relationship and communication can influence long-term health outcomes.2,3 This study generated a wide range of reactions on social media, with everything from “Of course women surgeons do a better job than men” to “This study is a lie.” Once we’ve processed our visceral reactions, as clinicians that prioritize our patients’ well-being above all else, we should be concerned that these results may represent a real disparity in health outcomes. The data scientists among us can and should do more work to investigate whether this association holds true in other populations. However, as surgeons, and even data scientists, we are poorly trained and poorly equipped to properly investigate whether the patient-surgeon relationship is the driver of these findings. We need to partner with those who have appropriate expertise, such as sociologists, to rigorously study this issue. In the meantime, this study reminds us that what all of us can do now, regardless of whether the findings are valid, is strive to treat each of our patients equally with the utmost compassion, respect, and diligence.

after surgery. The composite outcome rate was 14.9%.

Sex discordance between patient and surgeon was independently associated with a 7% increase in the likelihood of the primary outcome. Analyses stratified by physician, patient and hospital factors demonstrated that this effect largely persisted in the stratified analyses.

Further, among female patients, those treated by a male surgeon were 15% more likely to experience the primary outcome compared to those treated by a female surgeon.

In contrast, among male patients, those treated by a female surgeon Study highlights were no more likely to experience the primary outcome compared Christopher J. D. Wallis, to those treated by a male MD, an assistant professor surgeon. of urology at the University Poking holes in the way of Toronto in Canada, and the study was executed colleagues found that sex was proving to be difficult. discordance between the Certainly, the study suffered patient population and the 2,937 surgeons in the study from the limitations that are was associated with “a small inherent to all administrative but statistically significant data studies, namely lack increased likelihood of of granularity, which in adverse postoperative this case, as the authors outcomes.” This, the authors acknowledge, included noted, “was driven by worse the inability to outcomes for female patients distinguish between treated by male physicians sex and gender. without a corresponding The authors also association among male Karen Woo

patients treated by female physicians.”

References 1. W allis CJD, Jerath A, Coburn N, et al. Association of surgeon-patient sex concordance with postoperative outcomes.

JAMA Surgery. 2021;doi:10.1001/ jamasurg.2021.6339.

2. Coelho KR, Galan C. Physician cross-cultural nonverbal communication skills, patient satisfaction and health outcomes in the physician-patient relationship. International Journal of Family Medicine. 2012;2012.

3. Street RL, Makoul G, Arora NK, Epstein RM. How does communication heal? Pathways linking clinician–patient communication to health outcomes. Patient Education and Counseling. 2009/03/01/ 2009;74(3):295–301. doi:https://doi.org/10.1016/j.pec.2008.11.015.

KAREN WOO is associate professor of surgery at the University of California, Los Angeles (UCLA). She is also associate director of the Vascular Low Frequency Disease Consortium.

February 2022

NEWS

PAD

Trainee pipeline: ‘Recruiting more women without knowing the race/ ethnicity of those women only tells part of the story’ Failure to stratify gender by race or ethnicity, or vice versa, leads to missed opportunities in the recruitment of underrepresented members of the potential vascular surgery trainee pool.

THAT WAS ONE OF THE messages delivered in a poster presentation at the Southern Association for Vascular Surgery (SAVS) annual meeting in Manalapan, Florida ( Jan. 19–22). Among integrated vascular surgery residents in the U.S. and Canada in 2020, 63.2% identified as male, 53.9% as white, 7% Hispanic, 5.8% Black, 1.5% American Indian or Alaska Native, and 0.3% Native Hawaiian or other Pacific Islander, according to a research team that included first author Lauren N. West Livingston, PhD, and senior author Gabriela A. Velazquez, MD, of Wake Forest School of Medicine in Winston-Salem, North Carolina. Similarly, the analysis found that among vascular surgery fellows, 67.2% were male, 59.5% were white, 6.6% Hispanic, 3.5% Black, 0.4% American Indian or Alaska native, and 0.4% Native

Diversity dos and don’ts: Academic writing in the DEI space

BY JOCELYN HUDSON AND AARON KUDHAIL

I

t’s been almost 18 months since the Journal of Vascular Surgery (JVS) implemented changes aimed in part at diversifying involvement with the publication and addressing how papers on social determinants of health are written and reviewed.

Part of that process was the recruitment of a diversity editor. With more than a year under her belt in the role, Ulka Sachdev-Ost, MD, sat down with Vascular Specialist for a video interview during which she outlined milestones reached and how the journey has evolved so far.

She also had some tips for authors looking to write and report better academic papers in the arena of diversity, equity and inclusion (DEI) and healthcare disparities for publication in JVS and beyond.

Copious resources exist, she said, not least from Elsevier, the publisher of JVS, which has produced webinars covering

February 2022

Hawaiian or other Pacific Islander.

Livingston and colleagues used data drawn from the Association of American Medical Colleges compared with data on the sex/gender and race/ ethnicity of practicing vascular surgeons.

The researchers said the analysis demonstrated that minorities continued to be underrepresented in medicine but that the data were limited by training paradigm and did not examine results with an “intersectional lens.”

Analyzing the data in this way, they said, would have allowed further stratification of the figures by combination of race and gender, or the subgroups within certain racial/ethnic identities. “For example, recruiting more women without knowing the race/ethnicity of those women only tells part of the story,” the investigators said.—Bryan Kay DEI-related academic writing, and she encouraged authors to make full use of them. Further guidelines are planned by the JVS team on how to report on sex and gender, and social determinants of health, Sachdev-Ost added.

“These can help authors navigate some of the wording when you’re going to talk about women vs. females, and how to make that distinction in research, because it’s different when you’re talking about humans vs. whether you’re talking about animal research; how to incorporate socioeconomic and racial differences in your reporting, and what might be some of the best ways to make sure some of the appropriate stakeholders are included, or at least addressed in the correct way in the research,” she explained.

Look out for the full video interview with Ulka Sachdev-Ost at vascularspecialistonline.com.

“These can help authors navigate some of the wording when you’re going to talk about women vs. females” Ulka Sachdev-Ost

Atherectomy use during index intervention for claudication ‘is associated with higher’ reintervention rates vs. other technologies Atherectomy use during index peripheral intervention compared to “first quartile” vascular interventions in claudicants is atherectomy users—with those in quartiles associated with higher reintervention 1–3 being termed “inlier” physicians and rates when compared to other those in quartile 4 “outliers.” technologies, a newly unveiled study by Compared to vascular surgeons, Caitlin Hicks, MD, et al at Johns Hopkins cardiologists, radiologists, CT surgeons Hospital in Baltimore, Maryland, shows. and those from other specialties were The researchers found that 48.9% of also associated with higher risk for those who received an index atherectomy reintervention, the research team said. procedure later underwent reintervention, Other significant physician characteristics but just 29.8% of patients who did not included male sex and high volume undergo atherectomy did so. Some 59.7% peripheral vascular intervention practice, of the study group—drawn from 2019 Kawaji added. “Previously, physicians Medicare data on more than 15,000 patients working at OBLs [office-based labs] have intervened upon for claudication—received come under scrutiny for atherectomy use. index atherectomy, with the patient pool In our adjusted model, we did not find an followed through June 2021. Comparing association between site of service and reintervention between groups stratified by reintervention.” index procedure, Hicks et al revealed that Kawaji concluded: “Index 85.7% of patients undergoing femoropopliteal atherectomy a first-known intervention for claudication is associated with atherectomy also with high reintervention % % rates, and high atherectomy received a reintervention using the same procedure. physician users and This compared with just nonvascular surgeons Reintervention: perform more peripheral vascular 30.9% among those whose initial atherectomy vs. reinterventions than their peers. intervention was carried out non-atherectomy Because of the limitations of our using a different technology. The data were delivered by Qinqwen study, we were unable to elucidate Kawaji, MD, a general surgery resident, whether or not the high reintervention at the 2022 Southern Association for rates were related to atherectomy device Vascular Surgery (SAVS) annual meeting in failure or physician practice patterns.

Manalapan, Florida ( Jan. 19–22).

Our study suggests that appropriateness Probing physician side characteristics, for atherectomy use in initial peripheral the research team also found the estimated vascular reintervention for claudication 2.5-year cumulative incidence for firstneeds critical reevaluation.” time reintervention was 60% among The analysis builds on previous findings practitioners deemed high atherectomy

by Hicks and colleagues in recent years. users vs. 42.4% in those found to be Last year, her group reported on a study of standard atherectomy users (p<0.001). physician practice patterns using the same After adjusting for all patient Medicare dataset in which they found that characteristics, atherectomy continued to some 420 physicians, or 25.8%, performed be associated with a 33% higher risk for atherectomy in 87.5%-plus of their index reintervention, Kawaji told SAVS attendees. femoropopliteal disease intervention cases.

“Other characteristics associated with Another 133 physicians (8.2%) performed reintervention include Black race, diabetes atherectomy in 100% of their cases. and urban residence,” she said.

They also demonstrated that high users Meanwhile, patients treated initially by of atherectomy were more frequently high atherectomy user physicians were cardiologists or radiologists, and less associated with a 49% increased risk for frequently vascular surgeons.—Bryan Kay

48.9

29.8

Medtronic recalls HawkOne Medtronic has recalled 95,110 HawkOne directional atherectomy system devices distributed in the United States between Jan. 22, 2018, and Oct. 4, 2021, the Food and Drug Administration (FDA) has announced.

The FDA has identified the recall as Class I—the most serious type. So far, there have been 163 complaints, 55 injuries and no deaths reported in relation to the device issue, the FDA reported. HawkOne consists of a catheter and cutter driver, and is used during procedures intended to remove blockage from peripheral arteries. The recall was made “due to the risk of the guidewire within the catheter moving downward or prolapsing when force is applied during use,” according to the FDA.—Bryan Kay

vascularspecialistonline.com | 13

PEER REVIEW

Combating the problem of spin, or overinterpretation, in RCTs

BY BRYAN KAY

The presence of spin, or overinterpretation, in scientific papers that ultimately demonstrate statistically insignificant findings had been gnawing away at Thomas Forbes, MD, for quite some time.

THE PRACTICE, THE UNIVERSITY OF TORONTO vascular chair reflects, is by no means unique to vascular surgery but would often spring to the forefront of his mind as he pored over randomized controlled trials (RCTs) comparing endovascular aneurysm repair (EVAR) to open repair, and carotid stenting to endarterectomy (CEA).

In the case of EVAR vs. open repair, he recalls, he would see trial researchers with nonsignificant studies declare the former “no better” than the latter. “So, the new kid on the block is no better than the gold standard,” he says. “By saying no better, that has a negative connotation.” On the other hand, he would see authors involved with carotid stenting trials write that the new kid on the block—in this case, stenting—was “just as good as” the gold-standard CEA. “Whereas,” Forbes says, “statistically there was no difference. There was a positive connotation in one aspect, and a negative in the other.” The problem percolated in his mind, and together with a team made up of two

medical students and a cardiothoracic resident, he set about probing its extent in an analysis of abdominal aortic aneurysm (AAA) and carotid stenosis RCTs. What they found was that a large proportion of statistically nonsignificant RCTs yielded interpretations that were inconsistent with their results, disseminating them in a poster presentation at the 2022 Vascular Annual Meeting (VAM) in San Diego and again at last year’s annual meeting of the Canadian Society for Vascular Surgery (CSVS). They identified spin in nine abstracts and 13 main texts among 18 AAA articles, and seven abstracts and 10 main texts across 13 carotid stenosis studies. In reality, Forbes says, whether findings have a positive or negative connotation should be left to the interpretation of the reader. “As a reader, I should say, ‘With the new treatment, should I be disappointed that it is no better, or should I be happy that it’s just as good?’”

In their analysis, the researchers also looked at whether overinterpretation might be related to the publishing journal’s impact factor, the source of trial funding, and where exactly in the paper the spin occurred. No significant association was detected in terms of funding source, and increasing journal impact

“Try not to become a salesman for your science. Let it speak for itself” Thomas Forbes

factor was associated with a statistically significant lower likelihood of spin in the study title or abstract conclusion, the team reported. As for location, overinterpretation was “very common” in discussion sections, says Forbes.

“But I think, more importantly, it was also quite prevalent in the titles as well as the abstract conclusions.

Why I say that’s very important is I think readers of the scientific literature are deluged with massive amounts of information. And I’m sure most of us, if we’re honest, in our everyday practice, there’s very few papers that we read from front to back. There’s maybe a bit more where we actually read the entire abstract, and there’s maybe a bit more where we actually just read the conclusion of the abstract. So, spin, or overinterpretation of findings, in abstract conclusions and in titles has much more impact than the spin that occurs buried in the paper.”

It is incumbent on peer reviewers and editors to hold authors accountable for their wording so that overreach does not occur. “As an associate editor of the Journal of Vascular Surgery myself, that’s one of the big things that we go back and say to the authors,” Forbes explains.

“We say, ‘Look, you had a negative finding. Don’t give that negative or positive connotation. Just say you were unable to find a change.’”

Words matter, Forbes points out.

“Try not to become a salesman for your science. Let it Thomas speak for itself.”

Forbes

Join SVS in

Progress Precision Passion

Four full days of innovative learning, new formats, the latest research, discussion, exhibits and more.

Make Boston the next stop on your life-long journey of learning.

Save your seat for the

www.vascular.org/VAM 14 | Vascular Specialist

SVS Foundation's 'Cheers to 75 Years' Gala February 2022

CAROTID DISEASE

Novel use of TCAR to treat complex brachiocephalic disease shown to be effective, researchers report

BY BRYAN KAY

A “unique” case series of patients undergoing transcarotid artery revascularization (TCAR) in which the system was put to novel use for proximal intervention or incorporated in a hybrid approach to complex brachiocephalic disease demonstrated it to be effective in “providing safe, comprehensive treatment solutions,” the 2022 Vascular and Endovascular Surgery Society (VESS) winter annual meeting (Jan. 27–29) in Snowmass, Colorado, heard.

VIRAJ PANDIT, MBBS, DELIVERED the findings on behalf of a University of Oklahoma (OU), Tulsa, team of researchers led by vascular chief Peter R. Nelson, MD, informing delegates that a total of 94 patients underwent TCAR, with 8.5% (n=10) undergoing combined procedures. They found that two patients

had concomitant common carotid artery stenosis, four patients had subclavian artery stenosis and one had an occluded contralateral internal carotid artery. None in the combined group had postoperative complications—stroke, myocardial infarction or cranial nerve injury—and all were discharged home on postoperative

day one, Pandit added. TCAR same combination of treatment. We experience is expanding for the can do it through the less invasive treatment internal carotid artery approach of a TCAR. The technical stenosis, but its applicability in aspects are more or less how to patients with more complex maneuver the delivery system and brachiocephalic disease has not how to engage the flow protection Viraj Pandit been described, the researchers system that we’ve come to adopt reasoned as they set out to analyze the with TCAR.” Some of that older literature series. “suggests that doing tandem lesions had In that vein, they explored their experience with TCAR used in “This is obviously a small combination with other cerebrovascular number of patients, but interventions, including retrograde we’ve seen no increase common carotid artery stenting and carotid-subclavian bypass. “This unique in complications and case series of patients undergoing TCAR arguably similar or less in association with other cerebrovascular complications in this interventions demonstrated successful outcomes,” Pandit—formerly a vascular small group” surgery fellow at OU Health and now a Peter R. Nelson surgeon with VA in Fresno, California, and colleagues concluded.

Speaking to Vascular Specialist, senior author Nelson elaborated: “This paper increased complication rates—and we’ve probably falls between a traditional patient not seen that,” Nelson explained. “This is series and a technical note. Compared to obviously a small number of patients, but traditional literature, this approach seems we’ve seen no increase in complications applicable to the new technology. It doesn’t and arguably similar or less complications require endarterectomy to accomplish the in this small group,” he added.

VAM 2022: More science, discussion, streaming

"This will be a great opportunity to get back together, enjoy each other’s company and also support the important mission of the SVS Foundation” Andres Schanzer

BY BETH BALES

With abstract selection finished this month and the lineup of many other sessions in place, organizers are excited about the offerings of the 2022 Vascular Annual Meeting (VAM).

V

AM 2022 will be held June 15–18 at the Hynes Convention Center in Boston. Educational programming will be held all four days and exhibits will be open June 16–17. The Society for Vascular Surgery (SVS) Foundation “Cheers to 75 Years” Gala, celebrating the Society’s 75 years of treating patients with vascular disease, will be June 17.

Registration and housing are expected to open in earlyto mid-March.

Andres Schanzer, MD, chairs the SVS Program Committee, which oversees overall VAM programming.

He offered several innovations for the 2022 meeting, most made in response to participant feedback of previous iterations of VAM. VAM 2022 will include two additional podium-based plenary sessions, and eight overall. “This allows us to offer more science in the program and the opportunity to highlight more of our talented investigators,” said Schanzer.

There will be more discussion. This is a change based on overwhelming feedback from members who find the discussion period following abstract presentations very valuable, said Schanzer. Thus, the discussion period for

February 2022

SVS President Ali AbuRahma speaks during VAM 2021 in San Diego

the three-minute rapid-paced presentations has been extended from three to four minutes. “We hope this will allow for even richer discussion and exchange of ideas,” he added.

Two sessions will offer innovative formats, including visual abstracts and content shaped by social media as opposed to more standard didactic presentations followed by questions and answers.

“Members told us that livestreaming in 2021 was really valuable for those who couldn’t attend VAM in person so we have added more,” said Schanzer. “For 2022, we will again offer livestreaming of the morning sessions, which generally are plenaries, and we have added one full afternoon track on each day. We will also be livestreaming all of the international sessions in order to reach those who are unable to travel from abroad.”

Recording practices are being altered this year; Schanzer said the goal is to have all content available to VAM registrants rapidly. “We are shooting for an aspirational goal of having all video content of all presentations available on Monday, June 20, 48 hours after close of the meeting,” he said.

SVS members have been celebrating the Society’s creation in 1946 since the 2021 VAM in San Diego.

Festivities will culminate in the SVS Foundation Gala on the evening of Friday, June 17.

“We hoping it’s going to be the biggest and best VAM we’ve ever had,” Schanzer added.

For more information about VAM, including the meetings and conferences of the Vascular Quality Initiative and the Society for Vascular Nursing, visit vascular.org/VAM.

vascularspecialistonline.com | 15

ai16443378149_CX 2022 Ad Inhouse - FEB 2022-VSUSSIZE.pdf 1 08/02/2022 16:30:14

CONTROVERSIES

CHALLENGES

CONSENSUS

Vascular & Endovascular

Challenges Update C

REGISTER NOW

M

Y

CM

MY

CY

CMY

K

26–28 APRIL 2022 TUESDAY-THURSDAY

IN PERSON AND VIRTUAL

NEW VENUE H I LT O N L O N D O N M E T R O P O L E , U N I T E D K I N G D O M

Aortic Challenges

Peripheral Arterial Challenges

Venous & Lymphatic Challenges

Acute Stroke Challenges

Vascular Access Challenges

The Hurting Leg Challenges

WWW.CXSYMPOSIUM.COM

EDUCATION

INNOVATION

EVIDENCE

S

E

VASCULAR ANNUAL MEETING

VAM 2022 will offer innovative formats

BY BETH BALES

The Society for Vascular Surgery (SVS) Postgraduate Education Committee is breaking up the format in favor of change and innovation for two sessions at this year’s Vascular Annual Meeting (VAM).

These in-person-only events will involve both networking and social media.

Endovation: Endovascular Innovation for Urgent and Emergency Complex Aortic Disorders, 3–4:30 p.m., Wednesday, June 15 With “Endovation,” this concurrent session gets into the spirit of innovation, as its title suggests. It will bring together experts in “creative but understudied techniques” for complex aortic repair to discuss drawbacks, regulatory issues and best practices for those who are either considering or currently performing, off-label techniques in urgent and emergency settings.

“Endovation” starts with didactic podium presentations on various facets of the repairs, pre-recorded video

presentations of challenging aortic cases involving nontraditional surgical solutions, and a panel discussion.

The audience will be part of the conversation for discussion of the challenging cases. “Cases Under the Stars” encourages mingling and vascular conversation in a reception-type setting with light refreshments and beverages. Organizers may turn to social media to solicit the case-based content.

JVS Special Session, 1:30–2:30 p.m., Thursday, June 16 This special session highlighting the Journal of Vascular Surgery (JVS) publications will be an Audible Bleeding podcast using ESPN’s “Pardon the Interruption” program format.

As envisioned, panelists will cover a handful of provocative, entertaining topics. JVS editors will work with the SVS Social Media Subcommittee to solicit, via social media, interesting questions and topic ideas in advance of VAM. Audience involvement is key, said Paul DiMuzio, MD, assistant editor for social media for all JVS publications. He likened the informal give-and-take to “discussion around a workplace water cooler.”

The audience has the chance to pose any question they wish to those involved with the Journal of Vascular Surgery, at all levels of involvement in the publication process, DiMuzio said. Topics will be sought fairly close to the meeting itself, to ensure “the questions will be fresh

75th anniversary Gala tickets go on sale on Feb. 22

and topical,” said session organizer Gale Tang, MD. For example, in terms of diversity, equity and inclusion (DEI) issues, a member could seek to ask how the “be careful what you post in social media” article of 2020—which prompted a firestorm of criticism and plenty of social media posts of female doctors in swim attire—could possibly have made it through the review process.

Another member may want an answer as to whether published papers are even relevant in the era of social media/YouTube videos and sound bites.

The session will include a podcast with Imani McElroy, MD, one of Audible Bleeding’s regular personnel as a comoderator. It also will feature a short interview with Peter Gloviczki, MD, JVS editor-in-chief, while Peter Lawrence, MD, senior editor, will be on the panel answering questions. Gloviczki and Lawrence are completing their five-year terms at the head of the JVS publications.

Tang hopes participants will come away with “a better idea of what is involved with putting together the premier vascular surgery journal and how they can get involved with JVS at any career level.”

VAM takes place June 15–18, at the Hynes Convention Center in Boston. Registration and housing opens early to mid-March; educational offerings and plenary sessions take place across all four days; and exhibits are open June 16–17.

Meanwhile, the SVS Foundation “Cheers to 75 Years” Gala is June 17.

Visit vascular.org/VAM for more information.

awareness programs and patient education efforts, among other initiatives. Dress is semi-formal, with black-tie attire optional.

Everyone, no matter where in the world they are on June 17 can participate in the Silent Auction. All they need is an internet connection to be able to view the items and to place a bid.

Notifications will even let participants know when someone has upped the ante on a particular offering. Bidding for Silent Auction How will you help the Society for Vascular items will open several days before the Gala itself.

The 2019 “Vascular Spectacular Gala” in National Harbor, Surgery (SVS) celebrate “Cheers to 75 Years?”

Maryland, was a huge hit. Tickets sold out within weeks and MAYBE IT’S OFFERING AN ADVENTURE IN THE guests enjoyed dinner, entertainment and spirited bidding, and wilderness, on a mountain or secluded location. Perhaps it’s then danced the night away. providing the chance to stay in a house by the ocean or obtain a “You know how we surgeons are,” said Ronald Dalman, case of high-end wines put together by a connoisseur.

MD, Gala Committee chair. “If they’re not The committee overseeing this year’s SVS competing with each other to put together the Foundation Gala, “Cheers to 75 Years,” is seeking most elaborative and imaginative adventure contributions for both the live and silent auctions that possible, they’re preparing for the competition are a big part of the fun during the Gala. to outbid each other. We expect some great 0 0 $5 E This year’s Gala, to be held Friday, June 17, during items to be offered.”

N O IT ADM the 2022 Vascular Annual Meeting (VAM) celebrates Venita Chandra, MD, and Matthew the 75th anniversary of the founding of SVS in 1946.

Eagleton, MD, are the Gala Committee coThe celebration began in San Diego during the 2021 chairs.

VAM and will end with the last tune spun by the DJ While all contributions are welcome, TABLE OF 10 in June. the sub-committee handling ticket sales $5,000 Festivities begin at 6:30 p.m. at the Sheraton and auction items is particularly interested Boston Hotel, the VAM headquarters hotel. The in sporting events and skyboxes, sports evening starts with a reception, followed by dinner, memorabilia, travel and timeshares, food, entertainment, the live auction, raise the paddle event and entertainment, wine and high-end liquors, artwork, activities dancing. Tickets—sales open Feb. 22—are $500 each or $5,000 for such as golf, chef classes, jewelry and educational experiences.­— a table of 10. VIP tables and sponsorship packages are available Beth Bales now for purchase at vascular.org/Gala22Tickets.

All proceeds will benefit the SVS Foundation, to fund ongoing To donate, email Catherine Lampi at SVSFoundation@vascularsociety. research into the causes and treatments of vascular disease, public org. For information on the gala visit vascular.org/Gala22Tickets.

February 2022

GALA AT A GLANCE nS VS Foundation

“Cheers to 75 Years” Gala

n6 :30 p.m. Friday, June 17 nS heraton Boston Hotel

Grand Ballroom (the VAM 2022 Headquarters Hotel)

nR eception, which will

be followed by dinner, entertainment, live auction and dancing

nT ickets: $500 each or

$5,000 for a table for 10

nT icket availability:

Beginning Feb. 22

n I nformation and

tickets: Vascular.org/ Gala22Tickets; you cab also scan the QR code below

n Email: SVSFoundation@

vascular.org

vascularspecialistonline.com | 17

Subscribe today

October 2021 Issue 01 www.renalinterventions.net

In this issue:

Twelve-month Wrapsody results at CIRSE 2021 page 4

Alexandros Mallios page 12

Dialysis:

Latest debates in dialysis care page 17

Transplantation:

Healthcare disparities in the spotlight page 20

Renal community reckons with removal of race variable in kidney disease diagnosis

Bioartificial device receives KidneyX award after reaching preclinical testing AN IMPLANTABLE BIOARTIFICIAL kidney device (iBAK) has moved closer to becoming a reality after being awarded a US$650,000 prize from KidneyX. The device’s creator, the Kidney Project, received this award following the first ever demonstration of its functional prototype.

The Kidney Project is a US-wide collaboration led by Shuvo Roy (University of California San Francisco [UCSF], San Francisco, USA) and William Fissell (Vanderbilt University Medical Center, Nashville, USA).

In the past few years, it has successfully tested the two essential components that make up its artificial kidney technology—a haemofilter, which removes waste products and toxins from blood, and a bioreactor, which replic ates other kidney functions, like the balance of electrolytes in blood—in separate experiments.

To secure KidneyX’s Artificial Kidney Prize, the team married these two units in a scaled-down version of the artificial kidney that is roughly the size of a smartphone and evaluated its performance in a preclinical model following successful implantation. The units worked in tandem, powered by blood pressure alone, to provide continuous renal replacement therapy without the need for blood thinning or immunosuppressant drugs. This technology, which is intended to provide patients with improved mobility and physiological outcomes compared to dialysis, will now be upscaled for more rigorous preclinical testing and, eventually, clinical trials.

For the latest step forward in the development of this device, the Kidney Project team was awarded KidneyX’s Phase 1 Artificial Kidney Prize—becoming one of six winning teams selected from a field of innovators across Canada, Israel, Japan, The Netherlands, Portugal, Singapore, South Korea, the UK, and the USA. Other recipient technologies included a wearable, lightweight, dialysate-free artificial kidney (US Kidney Research Corporation) and genetically engineered pig kidneys designed to increase supplies of transplantable organs (Makana Therapeutics).

Profile:

iBAK device

(Credit: UCSF)

Follow Renal Interventions on all our social media platforms for the latest news, insight and events in kidney care

The National Kidney Foundation (NKF) and the American Society of Nephrology (ASN) have jointly released a report outlining a new race-free approach to diagnosing kidney disease. In its report, the NKF-ASN Task Force on Reassessing the Inclusion of Race in Diagnosing Kidney Disease recommends the adoption of the new estimated glomerular filtration rate (eGFR) 2021 Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) creatinine equation that estimates kidney function without a race variable.

and subsequent treatment of kidney diseases,” said ASN president Susan Quaggin. “By recommending the CKD-EPI creatinine equation refit without the race variable, the task force has taken action and demonstrated how nephrology continues to lead the way in promoting healthcare justice.

It is time for other medical specialties to follow our lead, and NKF and ASN stand ready to help however we can.”

In the USA, more than 37 million adults have kidney diseases and 90% are not aware they have diminished kidney function, the NKF-ASN statement adds, with a disproportionate number of these patients being Black or African American, Hispanic or Latino, American Indian or Alaska Native, Asian American, and Native Hawaiian or other Pacific Islander. These patient groups also face “unacceptable” health disparities and inequities in healthcare delivery.

he task force has also recommended the increased use of the protein cystatin C—a commonly used biomarker of kidney function—combined with serum (blood) creatinine as a confirmatory assessment of GFR or kidney function. The final report, which has been published online in the American Journal of Kidney Diseases (AJKD) and the Journal of the American Society of Nephrology (JASN), was drafted with “considerable input” from hundreds of patients and family members, medical students and other trainees, clinicians, scientists, healthcare professionals, and other stakeholders, to “achieve consensus for an unbiased and most reasonably accurate estimation of GFR”, according to a joint statement from the NKF and the ASN. “This recommendation by the NKF-ASN task force is an important step forward in assuring health and healthcare equity,” said NKF president Paul Palevsky. “We commend the task force for the time, thought, thoroughness and effort it took to explore this issue deeply, and recommend the best path forward for us all. The NKF and ASN urge all laboratories and healthcare systems nationwide to adopt this new approach as rapidly as possible so that we can move towards a consistent method of diagnosing kidney diseases that is independent of race. While the work of the task force is an important initial path forward, both of our organisations are committed to continuing to work to eliminate disparities in the diagnosis and treatment of kidney disease.”

“As the largest organisations representing kidney patients and health professionals, NKF and ASN are committed to eliminating health disparities that harm kidney patients, and ensuring that racial bias does not affect the diagnosis

Developing race-free recommendations Over a 10-month period, the NKF-ASN task force organised its work into three phases. The first involved clarifying the problem and evidence regarding eGFR equations in the USA; the second involved evaluating different approaches to address the use of race in GFR estimation; and the third involved providing recommendations based on this.

In April 2021, the task force published its interim report on reassessing the inclusion of race in diagnosing kidney diseases in AJKD and JASN, asserting that race modifiers should not be included in equations used to estimate kidney function, and that current, race-based equations should be replaced by a substitute that is “accurate, representative, unbiased and provides a standardised approach

T

“The NKF and ASN urge all laboratories and healthcare systems nationwide to adopt this new approach as rapidly as possible so that we can move towards a consistent method of diagnosing kidney diseases that is independent of race.”

Paul Palevsky Continued on page 2

Available in print and digital formats and through our social channels

Visit renalinterventions.net and click ‘Subscriptions’ for complimentary print subscription* and e-newsletter subscription**

A specialised news source in the field of renal disease management

A trusted provider of latest news, review of cutting-edge research, congress coverage and opinion from thought leaders

*Available for US and EU readers only **Available worldwide

Editorially independent

CONGRESS

SVS PAC: A voice for vascular surgeons on Capitol Hill

BY SHAHRAM AARABI, MD, YAZAN DUWAYRI, MD

As everyone turned the page on 2021 and entered 2022 with a new hope for a return to normalcy, vascular surgeons continue to be at the forefront of the fight to combat the COVID-19 pandemic.

OUR DAYS, AND NIGHTS, ARE taxing as we handle the challenging vascular manifestations of COVID-19, the life- and limb-threatening consequences of delayed medical care for chronic vascular conditions, the limited hospital bed capacity and the healthcare workforce shortages.

The resulting burnout, diminishing financial reimbursements and sluggish growth in the vascular surgery workforce necessitate a further push for vascular surgery’s seat at the legislative table as healthcare policies are developed that impact our patients and us.

In 2021, the Society for Vascular Surgery Political Action Committee (SVS PAC) focused on the following goals: nA dvocacy for fair and appropriate payment for vascular surgeons

February 2022

Time to pay 2022 dues

Shahram Aarabi

nA dvocacy for relief from regulatory

burdens such as prior authorization

nA wareness about physician wellness

issues

n Resolution of workforce attrition issues

Overall, the SVS PAC continues to grow in a positive direction, with 254 unique members (6% of the SVS membership).

Despite this growth, the SVS PAC lags other specialty societies in the amount and percentage of contributing members—a crucial metric to open the doors for our advocacy efforts in Congress. The SVS PAC aims to increase the percentage to 10% of the SVS membership as unique members of the PAC by the end of this election cycle, Dec 31, 2022.

In December 2021, because of multiple advocacy efforts by SVS PAC, Congress passed legislation to halt several Medicare

Yazan Duwayri

physician payment cuts including a delay in resuming the 2% Medicare sequester for three months ( Jan. 1– March 31), followed by a reduction to 1% for three months (April 1 to June 30); the erasure of the 4% Medicare PAY-GO cut and prevention of

Members, have any of you perhaps missed your most recent issue of the Journal of Vascular Surgery (JVS)?

If so, it could be because your 2022 Society for Vascular Surgery (SVS) dues have not yet been paid up.

As of Dec. 31, 2021, members with unpaid dues are no longer considered in good standing and thus unable to receive benefits such as a free or heavily discounted subscription to JVS. Membership suspensions and loss of all remaining benefits will begin in midFebruary.

Enjoy all the benefits that SVS membership has to offer and remit those 2022 dues today.

– Beth Bales

To register, visit vascular.org/Invoices.

any additional PAY-GO cuts through 2022; and a one-year increase over the Conversion Factor of 3% (0.75% less than the expired conversion factor “patch” provided for 2021).

However, the clinical labor update went into effect on Jan. 1, as year one of four.

These Medicare reimbursement results represent partial success of tremendous advocacy efforts, by the SVS PAC and other healthcare organizations. But, we still need your help as we continue to work on the clinical labor updates and its impact on office-based vascular surgery procedures.

Congress must hear your voice and the SVS PAC needs your continued support to do so. Please continue to contact your elected representatives and to contribute to the SVS PAC for 2022.

Vascular surgeons deserve representation equal to our role in the fight for a healthier society.

SHAHRAM AARABI and YAZAN DUWAYRI are members of the SVS PAC Steering Committee.

vascularspecialistonline.com | 19

VASCULAR PRACTICE

Office-based laboratory setting proves 'safe' for iliac vein stenting A retrospective study of 1,223 iliac vein cases performed in three office-based laboratories (OBLs) demonstrated a major complication rate of 0.41%, suggesting these procedures are safe and well-tolerated in this setting, the authors say.

ACCORDING TO CORRESPONDING researcher Levan Sulakvelidze, BS, from the Center for Vascular Medicine in Greenbelt, Maryland, “Because OBLs are not regulated to the same degree as inpatient facilities or ambulatory centers, questions have been raised regarding patient safety and outcomes in this environment.

“The safety profile of iliac vein stenting in the OBL setting has not been thoroughly evaluated. The purpose of

the present study was to evaluate the complication rate and safety profile of this procedure when performed in an OBL.” As reported in the January 2022 issue of the Journal of Vascular Surgery: Venous and Lymphatic Disorders, Sulakvelidze, senior author Peter Pappas, MD, part of the leadership at the Center for Vascular Medicine, and colleagues reviewed prospectively collected data from

FDA issues guidance documents for including patient perspectives in medical device studies The Food and Drug Administration (FDA) has issued two final guidances providing recommendations for including patient perspectives in medical device clinical studies.

AS PER AN FDA PRESS RELEASE, THE finalized version of the first of these two guidance documents, entitled “Patient Engagement in the Design and Conduct of Medical Device Clinical Studies,” features key points including: nD escribing how device developers, sponsors and industry can voluntarily use patient engagement to improve clinical study design and conduct nP roviding examples of approaches to consider when device developers, sponsors and industry wish to incorporate patient advisor input in clinical studies nD escribing which patient engagement activities are generally not considered by the FDA to constitute an activity subject to the FDA’s regulations regarding Institutional Review Boards (IRBs) nC larifying how sponsors can receive feedback from the FDA on plans to voluntarily include patient advisors’ input on their clinical study through the Q-submission process The second of these two newly issued guidances, entitled “Principles for selecting, developing, modifying, and adapting patient-reported outcome instruments for use in medical device evaluation,” intends to describe principles that may be considered for instruments that capture and measure patient-reported outcomes; provide recommendations about the importance of ensuring these instruments are fit-for-purpose; and outline best practices for selecting, developing, modifying, or adapting a patient-reported outcome instrument for use in medical device evaluation.—Jamie Bell 20 | Vascular Specialist

1,104 patients who underwent a total of 1,223 iliac vein stents in OBL centers.

Three patient groups were studied based on presentation: lower-extremity symptoms (305), pelvic symptoms (91) and, a combination of the two (827).

Trained nursing personnel, under the supervision of the attending interventionalist, administered conscious sedation to all patients. Typical dosing involved midazolam (1mg) and fentanyl (50µg). Excluded from this setting were patients with significant cardiac/ pulmonary risk, history of severe airway issues, morbid obesity and complex venous lesions (e.g., inferior vena cava [IVC] obstruction).

There were no mortalities and no complications related to the sedation rendered. The total complication rate was 7.8%, including five major complications (0.4%) and 90 minor complications.

Sulakvelidze comments: “In the study, because most of the complications were considered minor, including suspected over-

reported hematomas, we have presented strong evidence that demonstrates iliac stenting performed in the OBL setting is safe. Given these promising results, we recommend all OBLs become Joint Commission [formerly the Joint Commission on Accreditation of Health Care Organizations, or JCAHO]-certified and include quality assurance efforts to maximize patient safety.”—Bryan Kay

“Because OBLs are not regulated to the same degree as in-patient facilities or ambulatory centers, questions have been raised regarding patient safety and outcomes in this environment” Levan Sulakvelidze

VRIC input in 2021 helped strengthen research, says award-winner

BY BETH BALES

THE SOCIETY FOR VASCULAR Surgery (SVS) Vascular Research Initiatives Conference (VRIC) in 2021 helped Sriganesh (Sri) Sharma, MD, better understand his own work.

During the free-wheeling discussion following his presentation, “I got a lot of meaningful input into my research,” he said. “I was introduced to perspectives of my own research that I hadn’t thought of before.”

Under the mentorship of Andrea Obi, MD, at the University of Michigan, Sharma studied the intersection of inflammation and coagulation as it pertains to COVID-19 patients, with a goal of creating a therapy that would protect COVID-positive patients from blood clots. The timing was fortuitous; Sharma joined Obi’s lab with an interest in immunology, including the immunology of blood-clotting.

“The pandemic had just started,” he said. “It seemed like a very compelling question without many answers.”

The abstract on his research was not only selected for presentation at VRIC 2021 (held during the 2021 Vascular Annual Meeting) it also was judged as one of the top four among trainees, earning him and three researchers the SVS

Foundation VRIC Trainee Travel Award. (His conclusions: “The coronavirus infection inflammatory state induces MLL1 and urokinase expression in bone marrow derived Mφs and circulating Mφs. MLL1urokinase regulation contributes to the hyperfibrinolytic phenotype seen in critically ill patients with COVID19 and represents a potential immunotarget to curb fibrinolysis.”)

VRIC draws from throughout the field of vascular biology and the

“I love that the presentations are from different fields in vascular biology and from people at different levels of training” Sriganesh (Sri) Sharma conference is well-known for the robust and instructive discussion following presentations. “It’s a fantastic venue,” said Sharma. “I love that the presentations are from different fields in vascular biology and from people at different levels of training.”

“It’s a diverse crowd with diverse

perspectives,” Obi agreed. And because of that, plus the almost ubiquitous problem of blood clots from across almost all specialties and fields, Sharma said.

He has continued his work with Obi, with a manuscript set for publication, and he hopes his findings since a year ago, with much more now known, are selected for presentation this year.

“This is a fascinating subject to study. I thought it would be a flash in the pan when I started,” Sharma said. “But what we found is incredibly interesting and we want to learn more about it.”

Where the goal was once to create a therapy protecting COVID patients, the two now see broader applications.

“We’ve known for 30 years that these innate immune cells are involved in thrombosis” said Obi. “But to date, no one has come up with an immune therapy to target it.”

Those experiencing clots typically are put on blood thinners, but the side effect of bleeding can be problematic and sometimes lifethreatening.

“Maybe we can get rid of the clotting propensity without putting a patient on thinners,” said Obi. “That’s what Sri is studying.”

Coincidentally, given Sharma’s work in immunology, this year’s conference theme is “Translational Immunology and Cardiovascular Disease.” Sharma will feel at home.

VRIC 2022 will be held Wednesday, May 11, in Seattle. Registration has opened. Visit vascular.org/VRIC22 to register and for more information.

February 2022

COMMENTARY

Corner Stitch Diversity efforts while in training: Is it just another box to check?

BY CHRISTOPHER AUDU, MD

2020 was a herald year. It ushered in a global pandemic and a reckoning with issues of diversity, equity and inclusion (DEI) in our workspaces. Vascular surgery, by nature of the diseases we encounter and our longitudinal relationship with our patients, have been front and center in both the clinical and social effects of the pandemic. Resultingly, we have been at the cutting edge of surgical treatment for COVID sequelae, and have the opportunity to be at the center of effective diversity efforts. However, the plethora of DEI efforts sometimes seems overwhelming, superficial or forced; and to the vascular trainee—you!—it can be another item to check off our evergrowing competency list.

SO HOW DO WE BEGIN TO ENGAGE diversity, equity and inclusion efforts as a trainee in a meaningful way? If you’re like me, your plate is already full. There is no easy answer here, but from talking with colleagues who are also navigating this, and from taking notes from our colleagues in other specialties, here are a few simple ideas on how to approach this as a trainee.

Listening to our patients to really hear them Clinical medicine trains us to listen for buzz words, symptoms and pattern recognition. We learn much about pathophysiology. However, what we are not taught is how our patients experience the disease that we are tasked with helping them through. To get at this important and critical communication point, we must listen to what our patients are telling us and what is not being said. Ask open-ended questions without judgement. Acknowledge their reality.

If appropriate, verbalize the obvious emotion. Listen. Don’t rush to fill the silence void. Patients know you’re busy, and most want to respect your time, but what active listening does is communicate that their perspective is valued and heard.

To our minoritized patients, many of whom have been explicitly or implicitly told that their opinions, experiences and expressions don’t matter, this simple act is February 2022

much appreciated—even if you eventually have to relay bad news regarding their disease diagnosis and prognosis.

Everybody desires to be truly heard, and not summarily dismissed or ignored.

When you acknowledge the patient experience of their disease, both trainee and patient grow towards a common health goal.

cultural norms. As surgical trainees, who are often tired and running on caffeine, it can be easy to revert to how we see the world and assume that everyone sees it that way as well. It can be easy to revert to common stereotypes and tropes when that consult page comes in at the end of your call shift, or when you have to explain instructions to a difficult patient after you’ve just endured a negative evaluation, or when you finally get to see a patient who has “been lost to follow-up” or has “no-showed” clinic appointments.

This is not fair to the patient—nor to you, as a surgeon. We must seek to know our biases (there are several online tools for this), and then inwardly reflect on them.

This is easier said than done but the effort to do it will pay off, especially when communicating with our minoritized patients and/or anyone who doesn’t share the same heritage and upbringing as you.

And this brings me to my next point.

Sitting with discomfort and learning Sometimes, our biases show up when we least expect it. A situation may make us uncomfortable, unpleasant or upset—and we can’t put a precise finger on why. I love these moments, personally, because they reveal deeply held convictions, thoughts or experiences that beckon us to examine them thoughtfully. Other times, our biases are pointed out to us by our seniors, peers or friends. These are all opportunities for self-reflection, a resetting of our priorities, and if needed, personal education. Just as we strive to improve technically and in clinical judgement as our training goes on, and we constantly evaluate our

own performances when we hit negative feedback, I advocate that we sit with our discomfort and use it to propel us to grow.

Recruiting talent There is a linear relationship between being a trainee and increasing responsibility. One year you’re the medical student, and in a few short years, you become the chief. No matter where you are on this journey, you have the power to positively influence someone else, especially those who are historically underrepresented in our profession. These don’t have to be grandiose efforts. It can be as simple as giving positive feedback when someone does something right; or letting your junior know that you value them and their work; or helping someone navigate the hidden curriculum at your institution; or encouraging that student who is on the fence to seriously consider vascular surgery, letting them know that they belong. There is no doubt that having a surgeon who shares your experience and culture (and maybe even language) goes a long way in building a positive therapeutic alliance, and we should recruit as much talent to our team as possible. This list is by no means exhaustive. Rather, I write this to show that engaging in meaningful DEI efforts as a trainee doesn’t need big budgets or lofty programs to be impactful, but can begin with a kind word, a listening ear and a reflective attitude. To our minoritized patients, colleagues and juniors, these are what make a difference in the day-to-day grind that is vascular surgery. May we be up to the task of becoming competent, confident and compassionate surgeons.

Checking our implicit biases during patient care We all have biases based on our individual experiences, expectations, upbringing and

Apply for VAM travel scholarships Everybody desires by March 9 toMedical be truly heard,and general surgery students and not summarily residents have until March 9 to apply for Society foror Vascular Surgery (SVS) travel dismissed ignored

scholarships that enable attendance at the 2022 Vascular Annual Meeting (VAM) in Boston this June.

THE SCHOLARSHIPS ARE THE SVS GENERAL SURGERY Resident/Medical Student VAM Travel Scholarship and the SVS Diversity Medical Student VAM Travel Scholarship. Each provides not only a travel award to underwrite expenses to attend VAM, but also complimentary meeting registration, a mentorship program, mock interview practice session

and a dedicated educational and networking program.

Diversity scholarship winners also will participate in the Meet the Leaders Luncheon and Leadership Development Program graduation with members of the SVS Leadership Development and Resident and Student Outreach committees and mentors.

Students who live in the Boston area will not receive the travel award portion of the scholarship. Students and residents may apply to each scholarship program but are eligible to receive only one award per year. Priority will be given to those who have not previously received any type of SVS travel scholarship, are not presenting an abstract/poster at the meeting, and have not already matched into a training program. VAM 2022 will be held June 15–18 in Boston.

Scholarship notifications will occur in mid-April.—Beth Bales

More information is available at vascular.org/VAMTravel1 and vascular.org/VAMTravelDiversity.

vascularspecialistonline.com | 21

NEWS BRIEFS

Guidelines recognize potential role for earlier endovascular treatment of uncomplicated TBAD

BY WILL DATE

Newly published clinical practice guidelines aim to act as “guard rails” to determine the treatment options and best practices for managing patients with type B aortic dissection (TBAD). An important update in the document is the potential for earlier endovascular treatment in patients with uncomplicated TBAD at higher risk of progressive disease.

THE GUIDELINES, PRODUCED JOINTLY BY THE Society of Thoracic Surgeons (STS) and the American Association for Thoracic Surgery (AATS) were published online in the Annals of Thoracic Surgery and the Journal of Thoracic and Cardiovascular Surgery. The new document offers evidence-based recommendations that include employing a “stepwise approach” to the evaluation and treatment of patients with uncomplicated TBAD, followed by close clinical surveillance.

“There has been an explosion of information in the form of research reports of varying quality regarding the treatment of type B dissection over the past decade,” said author G. Chad Hughes, MD, from the division of cardiovascular and thoracic surgery at Duke University Medical Center in Durham, North Carolina.

According to the guidelines, aggressive medical therapy is the first step and considered the gold standard for managing patients with uncomplicated TBAD, while open surgery should be reserved for complicated cases.

Importantly, the guidelines recognize advances in less invasive treatment options for the disease, including the new role of earlier endovascular treatment such as thoracic endovascular aortic repair (TEVAR). They suggest that surgeons now may be able to identify subsets of patients with uncomplicated TBAD who have a higher risk of progressive disease and treat them earlier with TEVAR—before progression develops. But this advisory remains secondary to medical management.

“There has been an explosion of information in the form of research reports” G. Chad Hughes

Europe: ESVS PAD skills publishes 2022 course postponed guidelines on to October management of chronic venous Because of the surge in COVID-19 disease pandemic cases, the Society for Vascular Surgery (SVS) has postponed the planned SVS Complex Vascular Intervention Skills Course (formerly known as the Peripheral Arterial Disease Workshop) set for February to Oct. 23–24 in Rosemont, Illinois.

The decision followed careful monitoring by SVS of the pandemic and the recent surge in cases.

The decision was not made lightly; the top priority for the Society is the health and safety of SVS members and other learners.

Those who registered for the course, which will include hands-on skills training on Oct. 24, should check the email used for registration for refund and other important information.— Beth Bales

For information on the course and/or the postponement may contact the SVS education team at education@ vascularsociety.org or visit vascular.org/ PADCourse22.

Community practice award deadline extended The Society for Vascular Surgery (SVS) has extended the deadline to nominate an SVS member for the prestigious Excellence in Community Practice Award.

Applications now are being accepted through March 31 for this award, formerly known as the Excellence in Community Service Award. The honor is exclusively for those who practice in the community setting, including members in office-based labs (OBLs). Selection recognizes an individual’s sustained contributions to patients and their community, as well as exemplary professional practice and leadership.

To be considered, applicants must be community practitioners and have been in practice as a vascular surgeon for at least 20 years, been an SVS member for at least five years, and show evidence of impact on vascular care or community health.

Learn more at vascular.org/CommunityServiceAward.—Beth Bales February 2022

The European Society for Vascular Surgery (ESVS) has released 2022 clinical practice guidelines on the management of chronic venous disease (CVD) of the lower limb to update its 2015 recommendations.

The document, authored by Marianne De Maeseneer, MD, a venous specialist at Erasmus Medical Centre in Rotterdam, The Netherlands, and colleagues, was published online ahead of print in the European Journal of Vascular and Endovascular Surgery (EJVES).

The focus of the new guidelines is related to pathology of the superficial,

perforating and deep veins of the lower limb, as well as to abdominal and pelvic venous pathology.

Compared with the 2015 version of the guidelines, the authors communicate that the global structure of the document has been modified considerably in an attempt to make it more practical and user friendly.

In addition, they write that special subsections on management strategy with accompanying flowcharts have been added to the different chapters.

There are several new chapters in the 2022 document, addressing the management of patients with venous leg ulcers and of patients with varicose veins, related to underlying pelvic venous disorders, special patient characteristics and their potential influence on management strategy, and gaps in evidence and future perspectives.

De Maeseneer et al detail that five recommendations have been upgraded in the 2022 guidelines, with three downgraded.—Jocelyn Hudson

March 1 awards deadline nears

From the SVS journals The Journal of Vascular Surgery Cases, Innovations and Techniques has been growing rapidly, publishing an estimated 33% more articles this year than two years ago, according to JVS editors Peter Lawrence, MD, and Peter Gloviczki, MD. “In 2021, we modified the name of the journal to reflect its increased scope, which will now accept articles on all areas of innovation, including practice, education, outcome assessment and procedural technique as well.” See vsweb. org/JVSCITtransformation.

What’s the role of diet in managing PAD? JVS-Vascular Science discusses this topic in “Nutrition in the management of peripheral arterial disease: Should we pay more attention to what our patients eat?” See vsweb.org/ JVSnutritionandPAD.—Beth Bales

In memoriam Pinkus H. Szuchmacher, MD, of Manhasset, New York, died Aug. 8, 2021. Szuchmacher emigrated from Brazil in 1965 and spent 50 years in practice as a vascular surgeon— as well as training residents—in New York City. He was 81.

The deadline is March 1 for several awards and honors from the Society for Vascular Surgery (SVS) and the SVS Foundation.

They include the SVS Lifetime Achievement Award, the Medal for Innovation in Vascular Surgery, the Distinguished Fellow Designation, as well as SVS Foundation Clinical Research Seed Grants (writes Beth Bales).

■L ifetime Achievement Award: This is the highest honor the SVS bestows on an individual member. This recognizes an individual’s outstanding and sustained contributions to the profession and the SVS, as well as their exemplary professional practice and leadership. The most recent recipient was Robert Smith, MD, of Georgia (in 2020), who received his honor at the 2021 Vascular Annual Meeting (VAM) in San Diego ■ Medal for Innovation in Vascular Surgery: This honors an individual whose contribution has had a transformative impact on the practice or science of the vascular surgical specialty.

The most recent recipient was venous surgery pioneer Robert Kistner, MD, in 2019 ■ Distinguished Fellow designation: This designation goes to Active, International or Senior members who are vascular surgeons and who have made substantial contributions in two of the three categories of research, service and education. Visit vsweb.org/DistinguishedFellow for more information ■ Clinical Research Seed Grants: These awards provide $25,000 in direct support for clinical pilot projects that have the potential to become larger studies funded by industry or government sources

For more information on the awards, visit vascular.org/SVSAwards or vascular.org/ FoundationAwards. vascularspecialistonline.com | 23